

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Task-sharing with lay counsellors to deliver a stepped care intervention to improve depression, antiretroviral therapy adherence, and viral suppression in people living with HIV: study protocol for the TENDAI randomised controlled trial.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057844
Article Type:	Protocol
Date Submitted by the Author:	04-Oct-2021
Complete List of Authors:	<p>Abas, Melanie; King's College London, Section of Epidemiology, Health Services & Population Research Mangezi, Walter; University of Zimbabwe, Department of Primary Health Care Sciences, Unit of Mental Health Nyamayaro, Primrose; University of Zimbabwe, Department of Primary Health Care Sciences, Unit of Mental Health Jopling, Rebecca; King's College London, Health Service & Population Research Department Bere, Tarisai; University of Zimbabwe, Department of Primary Health Care Sciences, Unit of Mental Health McKetchnie, Samantha M.; Massachusetts General Hospital, Psychiatry; The Fenway Institute at Fenway Health Goldsmith, Kimberley; King's College London, Department of Biostatistics & Health Informatics Fitch, Calvin; Massachusetts General Hospital, Department of Psychiatry; Fenway Institute Saruchera, Emily; University of Zimbabwe, Department of Primary Health Care Sciences Muronzie, Thabani; University of Zimbabwe, Department of Primary Health Care Sciences Gudyanga, Denford; University of Zimbabwe, Department of Primary Health Care Sciences Barrett, Barbara; King's College London, Health Service & Population Research Department, Institute Of Psychiatry, Psychology & Neuroscience Chibanda, D; University of Zimbabwe, Department of Psychiatry; London School of Hygiene & Tropical Medicine, Centre for Global Mental Health Hakim, James; University of Zimbabwe Medical School Clinical Research Centre Safren, Steven; University of Miami, O'Cleirigh, Conall; Massachusetts General Hospital, Department of Psychiatry; Fenway Institute</p>
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Depression & mood disorders < PSYCHIATRY, HEALTH ECONOMICS, MENTAL HEALTH, PUBLIC HEALTH

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Task-sharing with lay counsellors to deliver a stepped care intervention to improve depression, antiretroviral therapy adherence, and viral suppression in people living with HIV: study protocol for the TENDAI randomised controlled trial.

Melanie Abas¹, Walter Mangezi², Primrose Nyamayaro², Rebecca Jopling¹, Tarisai Bere², Samantha M. McKetchnie^{3,4,5}, Kimberley Goldsmith⁶, Calvin Fitch^{3,5,7}, Emily Saruchera², Thabani Muronzie², Denford Gudyanga², Barbara Barrett¹, Dixon Chibanda^{2,8}, James Hakim^{2*}, Steven A. Safren⁹, and Conall O’Cleirigh^{3,5,7}

1. Health Service & Population Research Department, Institute of Psychiatry, Psychology, & Neuroscience, King’s College London, UK
2. Department of Primary Health Care Sciences, Unit of Mental Health, University of Zimbabwe, ZI
3. Behavioral Medicine Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA
4. School of Social Work, Boston College, Newton, Massachusetts, USA
5. The Fenway Institute, Fenway Health, Boston, Massachusetts, USA
6. Department of Biostatistics & Health Informatics, Institute of Psychiatry, Psychology, & Neuroscience, King’s College London, UK
7. Department of Psychiatry, Harvard Medical School, Cambridge, Massachusetts, USA
8. Centre for Global Mental Health, London School of Hygiene and Tropical Medicine, London, UK
9. Center for HIV Research in Mental Health, Department of Psychology, University of Miami, Coral Gables, Florida, USA

Corresponding Author:

Conall O’Cleirigh, Ph.D.
Massachusetts General Hospital
Harvard Medical School
Department of Psychiatry
Boston, MA USA
cocleirigh@mgh.harvard.edu

Trial registration: ClinicalTrials.gov Identifier: NCT04018391

Funding: R01 MH114708 awarded to Prof Abas and Dr O’Cleirigh by the National Institute of Mental Health (NIMH), NIH.

Date and Version: 22 September 2021, version 1.0

Conflicts of Interest: The authors do not have any conflicts of interest to report.

*Professor James Hakim was involved in the TENDAI study and this manuscript up until his death in 2020

Roles of Contributors

Melanie Abas: Dr. Abas is the King's College London PI for the trial and engaged in substantial writing of this manuscript.

Walter Mangezi: Dr. Mangezi is the University of Zimbabwe PI for the trial and engaged in revision of this manuscript.

Primrose Nyamayaro: Ms. Nyamayaro is the University of Zimbabwe Project Director for the trial and engaged in revision of this manuscript.

Rebecca Jopling: Ms. Jopling is the King's College London Project Director for the trial and engaged in substantial writing of this manuscript.

Tarisai Bere: Mrs. Bere is the University of Zimbabwe Clinical Supervisor for the trial and engaged in substantial writing of this manuscript.

Samantha M. McKetchnie: Mrs. McKetchnie is the trial Data Manager and engaged in substantial writing of this manuscript.

Kimberley Goldsmith: Dr. Goldsmith is the Trial Statistician and engaged in substantial writing of this manuscript.

Calvin Fitch: Dr. Fitch is the Massachusetts General Hospital Clinical Supervisor for the trial and engaged in revision of this manuscript.

Emily Saruchera: Mrs. Saruchera is the Senior Research Assistant for this trial and engaged in substantial writing of this manuscript.

Thabani Muronzie: Mr. Muronzie is a Research Assistant for this trial and engaged in substantial writing of this manuscript.

Denford Gudyanga: Mr. Gudyanga is a Research Assistant for this trial and engaged in substantial writing of this manuscript.

Barbara Barrett: Dr. Barrett is the Trial Health Economist and engaged in revision of this manuscript.

Dixon Chibanda: Dr. Chibanda is a Co-Investigator on this trial and provided guidance around the development and execution of this manuscript.

James Hakim: Dr. Hakim was a Co-Investigator on this trial and provided guidance around the development and execution of this manuscript up until his death in 2020.

Steven A. Safren: Dr. Safren is a Co-Investigator on this trial and provided guidance around the development and execution of this manuscript.

Conall O'Cleirigh: Dr. O'Cleirigh is the Massachusetts General Hospital PI for the trial and engaged in substantial writing of this manuscript.

Sponsor: The National Institute of Mental Health provides funding for this trial and monitors progress on the project through yearly Research Performance Progress Reports.

Abstract

Introduction: Non-adherence to antiretroviral therapy (ART) is the main cause of viral non-suppression and its risk is increased by depression. In countries with high burden of HIV there is a lack of trained professionals to deliver depression treatments. This paper describes the protocol for a 2-arm parallel group superiority 1:1 randomised controlled trial, to test the effectiveness and cost-effectiveness of the TENDAI stepped care task-shifted intervention for depression, ART non-adherence, and HIV viral suppression delivered by lay interventionists.

Methods and Analysis: Two hundred and ninety people living with HIV (PLHIV) aged ≥ 18 years who meet criteria for depression (Patient Health Questionnaire ≥ 10) and viral non-suppression (≥ 1000 HIV copies per ml) are being recruited from HIV clinics in towns in Zimbabwe. The intervention group will receive a culturally adapted 6-session psychological treatment including problem-solving therapy, positive activity scheduling, skills to cope with stress and poor sleep, and content to target barriers to non-adherence to ART. Participants with persistent depression step up to a nurse-evaluation for antidepressant medication. The control group receives usual care for viral non-suppression, consisting of three sessions of adherence counselling from existing clinic staff, and enhanced usual care for depression in line with the WHO Mental Health Gap intervention guide. The primary outcome is viral suppression (< 1000 HIV copies per ml) at 12 months post-randomisation. Ethics and Dissemination: The study and its tools were approved by MRCZ/A/2390 in Zimbabwe and RESCM-18/19-5580 in the United Kingdom. Study findings will be shared through the community advisory group, conferences, and open access publications.

Strengths and Limitations:

Strengths:

- The first randomised controlled trial in a low-income country to test an intervention to improve both adherence to antiretroviral therapy and depression in people living with HIV.
- Culturally adapted and culturally appropriate intervention to address barriers to adherence to antiretroviral therapy and to treat depression, based on extensive preliminary work.
- Cost-effectiveness under investigation.
- Stepped care intervention be delivered through task-shifting to non-specialist staff, allowing for future scale up.

Limitation:

- Limited scope to assess implementation science questions given the individually randomised design.

Introduction

Over 27% of people in sub-Saharan Africa currently receiving antiretroviral therapy (ART) are non-adherent (1), and non-adherence to ART is the main cause of viral non-suppression (2). Depression is among the strongest correlates of non-adherence and affects over 15% of PLHIV attending HIV out-patient clinics in sub-Saharan Africa (1, 3, 4). Depression is linked to non-adherence through the reduced motivation and forgetting to take ART (5), through impaired problem-solving ability (6), and through interfering with uptake of existing adherence support programs. Depression may also impact adherence through its association with structural factors, such as poverty, and interpersonal difficulties which impede access to HIV medication (5, 7, 8). Non-adherence to ART may also precede and increase risk of depression (9).

Countries with high burden of HIV, such as Zimbabwe, have a dearth of trained mental health professionals. Given the public health importance of viral suppression (10), and the strong association with depression, adherence interventions must address comorbid psychological factors and be able to be delivered through task-shifting to non-specialists (11). Systematic reviews of mental health interventions in PLHIV in low resource settings have been unable to report effects on HIV outcomes as, to date, these have not been studied (12, 13).

The most promising evidence for the effectiveness and utility of integrated treatments for

1
2
3 depression and ART adherence for PLHIV has come from the development of Cognitive
4 Behavioural Therapy for Adherence and Depression (CBT-AD) in the United States (14, 15).
5
6 CBT-AD, which includes the “Life Steps” intervention for addressing barriers to medication
7 adherence, has been shown to improve rates of ART adherence, and to reduce depression
8 severity among men in the US (16 , 17). In contrast, interventions for PLWH with depression
9 and poor adherence which *only* target mood have not been found to improve viral suppression
10 (18). Recent reports, including from our team in Zimbabwe, support the acceptability and
11 feasibility of culturally-adapted CBT-AD for low resource settings (19-21). However, there have
12 yet to be any definitive RCTs from low resource settings focused on treatment of depression and
13 ART adherence to improve viral suppression (22). Thirteen percent of the adult population in
14 Zimbabwe is living with HIV, with 22% of those virally non-suppressed (22). The objective of
15 this trial is to test the effectiveness and cost-effectiveness of the TENDAI stepped care
16 psychological intervention for adherence to ART and depression, (Stepped Care-AD), compared
17 to enhanced usual care, for PLHIV in Zimbabwe with viral non-suppression and depression.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **Methods and Analysis**

37 **Study Design and Setting**

38
39
40
41
42 The study is a two-arm parallel group superiority 1:1 randomised effectiveness trial
43 (n=290). PLHIV receive care according to the standard national guidelines (23). Viral load is
44 monitored every 12 months, with more frequent screening every 3 months for those who are
45 virally non-suppressed. Participants are being recruited from two sites in Zimbabwe providing
46 HIV services for those initiated on ART. These are the Marondera Provincial Hospital, and
47 Chitungwiza Central Hospital, along with satellite clinics for each hospital. Marondera is the
48 capital of Mashonaland East province, situated in the north east of Zimbabwe. The town and its
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 surrounding district have a total population of approximately 224,000 (24). Chitungwiza is an
4
5 urban town, divided into five townships, with a total population of approximately 391,000 (25).
6
7 Taken together, both sites combined have approximately 25,000 adults registered as receiving
8
9 ART.
10

11 12 13 **Patient and Public Involvement**

14
15
16 No patient involvement in the design of the study. Results will be disseminated to study
17
18 participants and community members via local advisory groups.
19
20

21 **Eligibility Criteria**

22
23
24 Inclusion criteria: 1) HIV positive and initiated on ART for at least 6 months; 2)
25
26 clinically significant depression symptoms (operationalised as a score of 10 or more on the
27
28 locally validated Patient Health Questionnaire (PHQ-9) (4); 3) virally non-suppression in the past
29
30 2 months (viral load \geq 1000 copies/mL); 4) able to provide informed consent ; and 5) if
31
32 prescribed anti-depressants, be on a stable regimen for at least 2 months. Exclusion criteria: 1)
33
34 unwilling or unable to provide informed consent; 2) major untreated or undertreated mental
35
36 illness (e.g. untreated psychosis or mania, actively suicidal), major or advanced physical disease
37
38 or severe cognitive impairment which would interfere with engagement in Stepped Care-AD; 3)
39
40 have received a course of problem solving therapy or cognitive-behavioural psychological
41
42 therapy for depression; or 4) $<$ 18 years old.
43
44
45
46
47

48 **Study Procedures**

49 50 51 **Recruitment and Informed Consent**

1
2
3 Research Assistants (RAs) in the ART clinic approach patients identified by clinic staff
4 as having a detectable viral load (>1000 copies/mL) in the past 2 months or at high risk of viral
5 non-suppression, e.g self-reported poor adherence. Potentially eligible individuals will complete
6 a brief screen for inclusion and exclusion criteria. Those meeting initial screening eligibility
7 criteria are invited to complete informed consent procedures and the full baseline assessment.
8 Informed consent will include consent to access participants' medical records, and for telephone
9 calls and home visits if needed for follow-up. Capacity to provide consent is assessed by a
10 licensed psychiatrist (WM) for any participant indicating consent but suspected of being unable
11 to fully understand and/or retain information provided.
12
13
14
15
16
17
18
19
20
21
22
23

24 **Baseline**

25
26
27 A trained RA collects data by face-to-face interview including: demographics, HIV
28 characteristics, measures of socio-economic position (26, 27), depression using the Patient
29 Health Questionnaire (PHQ-9) (4), anxiety using the Hospital Anxiety and Depression Scale (28)
30 quality of life using The EQ-5D-3L (29), use of alcohol and substances (30, 31), cognitive
31 impairment using the International HIV Dementia Scale (32), psychiatric diagnosis using the
32 MINI International Neuropsychiatric Interview (33), use of health services in the last 4 months
33 using a modified version of the Client Services Receipt Inventory (31) and several additional
34 exploratory measures.
35
36
37
38
39
40
41
42
43
44
45

46
47 Viral load in the past 60 days is ascertained from the participants medical records, or, for
48 those who have not been tested in the past two months, by testing plasma. Current ART regimen
49 and recent CD4 test results are taken from participants medical records. A blood sample for dried
50 blood spot (DBS) is used to detect the presence of ART medications (34).
51
52
53
54
55
56
57
58
59
60

Eligibility

The study team, including a clinical psychologist or psychiatrist, will meet weekly via teleconference to discuss each baseline assessment and confirm that participants meet eligibility criteria.

Randomisation

Approximately 2 weeks after the baseline assessment, eligible participants return for a randomisation visit and are randomly assigned to Stepped Care-AD or enhanced usual care (EUC). Randomisation is determined by a computer-generated chart and is conducted via the REDCap randomisation module by the Zimbabwe site Programme Manager.

Follow-Up Assessments

In addition to baseline, there are 3 major study assessments: 4-, 8-, and 12-months post-randomisation. An Independent Assessor (IA) who is blind to study condition will administer the PHQ-9, EQ-5D-3L, and self-report medication adherence measures. RAs will collect self-report data including use of alcohol and substances (30, 31), Hospital Anxiety and Depression Scale for Anxiety (28), quality of life (29), and use of other health care services (35). At the final 12-month follow-up, we will also extract chart information from medical records for pharmacy refill data and HIV viral load results. Participants without a viral load test in the past 30 days are invited to undergo venepuncture for viral load testing, which is in addition to the venepuncture for ART detection.

Interventions

1
2
3 **Active Intervention Arm: Task-sharing Stepped Care Intervention for Adherence**
4 **and Depression (TENDAI Stepped Care-AD).**
5
6
7

8 As shown in Figure 1, all participants in the TENDAI arm receive six 50-minute sessions
9
10 of a culturally adapted intervention for depression and non-adherence to ART, followed by one
11
12 booster session six weeks later. The intervention is based on cognitive behavioural principles and
13
14 includes problem-solving therapy, positive activity scheduling, skills to cope with stress and poor
15
16 sleep, and content to target barriers to non-adherence to ART. Training of interventionists
17
18 emphasises common elements of effective psychological interventions including empathy, active
19
20 listening, and creating realistic hope (36).
21
22
23
24

25 A) Adherence to antiretroviral therapy. Session 1 comprises a locally adapted version of
26
27 the Lifesteps adherence intervention called *Nzira Itsva* (14, 37). This includes motivation, goal
28
29 setting, video-based education and problem solving. Motivational interviewing is used to identify
30
31 the participants life goals and to tie adherence to achieving these goals. Education about on time
32
33 adherence is provided using an animated video in the Shona language. Barriers to adherence are
34
35 assessed through a culturally adapted checklist. During each of the subsequent sessions 2-6
36
37 targeting depression, 5- to 10-minute adherence boosters are included to review adherence to
38
39 ART and the participants' experience with strategies to overcome barriers to adherence.
40
41
42
43

44 B) Psychological intervention for depression. Sessions 2 and 3 focus on psychoeducation
45
46 about depression and problem-solving therapy (PST) (38), incorporating storytelling and
47
48 illustrations, and training in problem-solving. A goal for each session is to identify a defined
49
50 specific problem to work on, to collaboratively agree a solution to work on and to schedule
51
52 homework. An intervention based on PST has been shown to be acceptable and effective for
53
54 depression in Zimbabwe (39, 40). In Session 4 participants are encouraged to choose and
55
56
57
58
59
60

1
2
3 schedule at least four adaptive activities in which to engage: an activity that promotes a sense of
4 achievement, a physical activity, a pleasurable activity, and a social activity. Homework is
5 mutually agreed as part of every session, to test out participants' implementation of solutions to
6 problems, and of positive activities. Thorough review of homework is done at each session,
7 including barriers to doing homework. Skills to promote good sleep and relaxation are taught in
8 Sessions 5 and 6. A relapse prevention plan is developed in session 6 including triggers for
9 relapse of depression, warning signs, coping strategies and self-care activities. Fidelity of the
10 intervention will be assessed through rating 10% of audio-recorded sessions for adherence to the
11 intervention protocol and for therapist competence (41).
12
13
14
15
16
17
18
19
20
21
22
23

24 C) Booster session. About six weeks after the sixth session, participants are invited to a
25 50-minute booster session. This includes a review of depressive symptoms, and of adherence to
26 HIV treatment and, where appropriate, adherence to antidepressant medication. The session
27 includes ongoing positive activity scheduling to promote recovery from depressive symptoms.
28
29
30
31
32
33

34 D) Stepped up care. Participants with persistent depression after at least 4 sessions
35 receive step up to a nurse-evaluation for antidepressant medication. The antidepressant
36 Fluoxetine is offered for those with confirmed depression.
37
38
39
40
41

42 **Control Arm: Enhanced Usual Care (EUC)**

43
44

45 All participants in the control arm receive Enhanced Usual Care (EUC) comprising usual
46 care for viral non-suppression, and enhanced usual care for depression in line with the WHO
47 Mental Health Gap intervention guide. Usual care for those with viral non-suppression includes
48 three sessions of adherence counselling provided by an adherence counsellor, nurse, or NGO
49 support worker based at the clinic. These sessions include establishing the participants
50
51
52
53
54
55
56
57
58
59
60

1
2
3 knowledge about HIV and ART, providing information about use of ART, encouraging
4 adherence, and describing barriers to adherence. Strategies commonly used include encouraging
5 use of an alarm and a treatment supporter, linking ART taking to daily routines, and disclosure of
6 HIV status. The first session is given on the day of receiving viral load results, with two
7 subsequent sessions scheduled on a monthly basis. Referrals may be made to local support
8 groups or organisations for social or economic support, general psychological support or to an
9 HIV clinician. The HIV operational strategy recommends that all patients living with HIV and
10 registered at facility should be screened for common mental disorders (CMD) annually. Patients
11 with high viral load or those initiating ART should be screened for CMD at their appointment
12 (42). Patients exhibiting symptoms of common mental disorders or psychological distress should
13 be managed with counselling interventions and are usually referred to the outpatient's
14 department to be assessed by a Psychiatric nurse. If they require further treatment, they will be
15 seen by a psychiatrist. Patients can also be referred to community-based organization to receive
16 psychosocial services (42). Usual care for depression is enhanced in three ways: 1) The study
17 team will train all health service providers in the study sites on psychological and antidepressant
18 management of depression using the WHO Mental Health Gap intervention guide (mhGAP)
19 (43); 2) we will provide a letter for each participant communicating diagnosis of depression to
20 their HIV-care provider; and 3) we will provide those in the EUC condition with access to
21 Stepped Care-AD upon completion of their 12-month follow-up visit.

47 **Outcomes**

50 **Primary Outcome**

51
52
53 Viral suppression at 12-months post-randomisation follow-up (defined as <1000
54 copies/mL), measured through blood (plasma). This measure will be taken from the medical
55
56
57
58
59

1
2
3 record if viral load was collected within 30 days of the expected visit date or through study
4
5 specific assay if not in the medical record.
6

7 8 **Secondary Outcomes**

- 9
10
11 1. Depression at 12 months post randomisation measured as the total score on the Patient
12
13 Health Questionnaire (PHQ-9) (4).
14
15 2. Adherence to ART medication at 4-, 8-, and 12-months post randomisation assessed as
16
17 the proportion of the sample achieving at least 90% adherence in the past month assessed
18
19 through pharmacy refill (44).
20
21 3. Self-reported adherence to ART medication at 4-, 8-, and 12-months post randomisation
22
23 assessed as the frequency of adherence in the past 30 days (45).
24
25 4. Viral load copies/mL at 12-months post-randomisation follow-up measured as mean log
26
27 Viral Load.
28
29
30

31 **Tertiary Outcomes**

32
33
34 The total costs of the health care services used by each study participant will be
35
36 calculated using service use information collected from hospital records and from participant
37
38 self-report (via a modified version of the Client Services Receipt Inventory suitable for use in
39
40 sub-Saharan Africa (35)) at 4-, 8-, and 12-month follow-up and with unit costs identified and
41
42 calculated using locally available data. Detailed information on the use of Stepped Care-AD and
43
44 EUC will be collected from therapist records. Quality of life at 4, 8 and 12 months is measured
45
46 using EQ-5D-3L (29). Quality-adjusted life years will be calculated using Zimbabwe-specific
47
48 health states (34).
49
50
51
52

53 **Data Collection and Management**

1
2
3 Trial data is collected and stored in REDCap, a data management tool designed for
4 collection and protection of patient health information. The REDCap database is hosted and
5
6 routinely audited at Massachusetts General Hospital (MGH), with access restricted via user roles.
7
8 Data extracts are sent to the study statisticians, via secure file transfer. To ensure accuracy of
9
10 collected data, MGH staff generate weekly error reports. These error reports are then sent to staff
11
12 in Zimbabwe, who correct any discrepancies and document changes made to the database.
13
14
15

16 17 **Strategies to Improve Participant Retention**

18
19
20 Procedures to maximise participant retention include reimbursing participants for
21
22 attending study visits (equal amount in both arms), sending text message reminders before
23
24 scheduled appointments and collection of locator information (e.g., contact information of two
25
26 significant others with whom the participant is in regular contact). We will make efforts to retain
27
28 individuals who move to a non-study site for their HIV care and are willing to complete follow-
29
30 up. Where participants are unable to travel to the clinic to complete follow up assessments (e.g.
31
32 because of COVID-19 lockdown travel restriction), participants will be offered phone
33
34 assessments. Where participants can not be reached by phone, a home visit may be conducted.
35
36
37
38

39 40 **Ethics**

41
42
43 All study procedures were reviewed and approved by ethics committees at King's
44
45 College London (RESCM-17/18-5580), Massachusetts General Hospital (IRB00012706), and
46
47 the Medical Research Council of Zimbabwe (MRCZ/A/2390). SAEs will be reported to research
48
49 ethics committees at King's College London, MGH, and the Medical Research Council of
50
51 Zimbabwe within 72 hours.
52
53

54 55 **Confidentiality**

1
2
3 Participants are given a study-specific identification number at screening that is used on
4 all forms and data collection instruments, excluding the consent form. participants are referred to
5 only by their identification number during eligibility and supervision meetings. A file that links
6 participant names to identification numbers is stored in a locked file at the University of
7
8 Zimbabwe.

15 **Blinding**

18 To reduce bias and maximise the validity of the findings, the Independent Assessor (IA)
19 for the primary and secondary outcomes, and the lead study statistician, is blinded to
20 randomisation condition. To ensure blinding, the IA will explain their role to participants and ask
21 that they do not give the IA information about the treatment they received. The lead study
22 statistician will not attend meetings where randomisation or clinical issues are discussed, and
23 their access in REDCap is restricted so that they cannot view any data or report that may unblind
24 them. A second statistician, who will conduct the analyses and will review data for thoroughness
25 and completeness, will not be blinded. This trial does not have procedures for unblinding IAs or
26 the lead study statistician. If the IA is concerned about the safety of a participant, they will
27 communicate the concern to study staff, who will contact the clinical supervisor.
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Data Safety and Monitoring Board (DSMB)**

45 A DSMB, consisting of members with experience in clinical trials for mental disorders,
46 biostatistics, HIV in African settings, and human subject protection issues will function
47 independent of the sponsor and monitor safety of study participants and integrity of data. The
48 DSMB will meet annually and receive safety information in an unblinded manner. Expedited
49 review by the DSMB will occur for all serious adverse events (SAE) as defined as any fatal,
50
51
52
53
54
55
56
57
58
59
60

1
2
3 immediately life-threatening, or substantially disabling event; event requiring or prolonging
4
5 inpatient hospitalisation, or any congenital anomaly.
6
7

8 **Statistical Methods**

9 **Sample Size**

10
11
12
13
14 Using two-sided Fisher's exact test, $\alpha = 0.05$ and 20% attrition, a sample size of 290
15
16 participants will provide 85% power to detect an absolute difference of 20% or more in
17
18 achieving viral suppression (e.g. 45% in the EUC arm vs. 65% in the intervention arm) at 12-
19
20 months follow-up. Pilot data showed a larger difference between arms (50% in the EUC arm vs.
21
22 75% in the intervention arm) (20), suggesting this should be a conservative sample size estimate.
23
24
25

26 **Statistical Methods for Primary and Secondary Outcomes**

27
28
29 Baseline and outcome variables will be summarised using appropriate statistics; no
30
31 baseline statistical comparisons will be made. The main analysis will follow intention to treat
32
33 principles as much as possible, reporting appropriate 95% confidence intervals and use a 5%
34
35 significance level. All models will include a site stratification variable. In the mixed models we
36
37 will have random intercepts at the participant level, and random slopes if warranted (assessed via
38
39 likelihood ratio test).
40
41
42
43

44 Twelve-month primary outcome viral load will be coded as suppressed (<1000
45
46 copies/mL) vs not suppressed (≥ 1000 copies/mL). Where these data are missing, the individual
47
48 has died, and medical or death records indicate death due to high viral load/death was AIDS
49
50 related, they will be coded as not suppressed, otherwise the outcome will be left missing.
51
52

53 Suppressed/not suppressed will be the dependent variable in a logistic regression model
54
55 estimating the TENDAI vs EUC odds ratio (OR), with trial arm as the independent variable. The
56
57
58
59

mean difference in PHQ-9 depression and self-report adherence will each be estimated using a linear mixed effects model with the 4-, 8- and 12-month measures as dependent variables, with the baseline measure of the outcome, time, and trial arm by time interaction terms as independent variables. The OR at 4, 8 and 12 months for $\geq 90\%$ adherence vs $< 90\%$ adherence by pharmacy refill in the past 30 days will be estimated using a logistic mixed effects model with the 4, 8 and 12-month measures as dependent variables, and independent variables as described for PHQ-9 and self-report adherence. The mean difference in log copies/mL of viral load at 12 months will be estimated using a linear regression model with log viral load at 12 months as the dependent variable, trial arm and baseline log viral load as independent variables.

A “per protocol” analysis for the primary viral load outcome only will exclude participants not completing at least four TENDAI sessions, and anyone found to be ineligible post randomisation. No interim or formal powered subgroup analyses are planned, however, we will explore moderation by sex for viral suppression, self-report adherence and depression outcomes by adding a sex by trial arm (by time, where appropriate) interaction term to the final outcome analysis models. Additional exploratory mediation analysis is planned, but will not be reported on in the main paper. Missing baseline measures will be imputed using simple mean imputation (46). Missing repeatedly measured outcome data will be handled using mixed models/maximum likelihood methods, including baseline variables predicting missing outcome data. If there is more than 10% missing primary outcome data and post-randomisation variables (completion of therapy in the TENDAI arm only and ART adherence at 12 months) predict whether these data are missing, we will consider multiple imputation (MI) (47).

Cost-effectiveness results will be reported following CHEERS guidelines (48). First, the mean average total cost in each randomised group will be calculated and compared between the

1
2
3 two groups using standard t-tests, despite the likely skewed nature of the data because of a
4 preference for reported means in costs (49). As is common in the analysis of cost data, the
5 robustness of the mean cost comparisons will be confirmed through the calculation of
6 nonparametric bootstrapped confidence intervals (50). The primary cost-effectiveness will
7 consider costs together with the dichotomous primary outcome measure (viral suppression <1000
8 copies/mL), generating information on the cost per successful case and the probability that the
9 PST-AD is cost-effective compared to enhanced usual care given available information. A
10 secondary cost-utility analysis will also be completed, which will report the cost per QALY of
11 stepped care-AD intervention compared to enhanced usual care. Analyses will be adjusted for
12 costs and outcomes. Sensitivity analyses will be carried out to test the robustness of costing
13 assumptions to variation.
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 29 **Dissemination**

30
31
32 Dissemination of findings will involve three primary papers describing the study
33 outcomes, as well as submitting to lead workshops on the treatment approach at relevant national
34 meetings and conferences. Additionally, data will be available to external parties after
35 publication of the outcome papers via PI-approved application. Data will be stored indefinitely.
36
37
38
39
40
41
42
43
44
45

46 **Discussion**

47
48
49 In Zimbabwe, both HIV and co-morbid depression are common, yet, as in other low-
50 resource settings with high HIV burden, there is a lack of evidence on interventions to improve
51 both ART adherence and depression (51, 52). Due to resource limitations, interventions that
52
53
54
55
56
57
58
59
60

1
2
3 allow for task-shifting and administration by community health workers are particularly well-
4 placed to be effective and sustainable. Our treatment, Stepped Care-AD, blends active
5 ingredients of treatment for depression with a culturally-adapted LifeSteps intervention to
6 enhance adherence to ART (20, 37). If successful, the Stepped Care-AD intervention represents a
7 useful model for policy and for further research. As the primary outcome of the trial is viral
8 suppression, its implementation in Zimbabwe and other low-resource settings may further the
9 UNAIDS goal of ending the AIDS epidemic by 2030, through optimising viral suppression (53).
10 Results gathered in a Zimbabwean context may be leveraged for testing and implementation of
11 similar task-shifted stepped care interventions in other Sub-Saharan African settings.
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **Trial Status**

26
27
28 This trial began recruitment and enrolment on 2nd July 2019.
29
30

31 **Acknowledgements**

32
33
34 Mercy Mundwa, Oline Chivere, Sheila Marezva, Vimbai Gwata, Rumbidzai Nyanda,
35 Moreblessing Phiri, Megan R. Wirtz, Rachel Holland, Dr Tsitsi Apollo, Dr Celestino Dhege, Dr
36 Michael Chiwanga, Tinashe Macheke, and Isaac Masarira,
37
38
39
40

41
42 KG contributions to this paper represent independent research part funded by the NIHR
43 Biomedical Research Centre (South London and Maudsley NHS Foundation Trust and KCL) and
44 the NIHR Applied Research Collaboration South London (King's College Hospital NHS
45 Foundation Trust). The views expressed are those of the author(s) and not necessarily those of
46 the NHS, the NIHR or the Department of Health and Social Care.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Heestermans T, Browne JL, Aitken SC, Vervoort SC, Klipstein-Grobusch K. Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review. *BMJ Glob Health*. 2016;1(4):e000125.
2. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. *The Journal of infectious diseases*. 2008;197 Suppl 3:S272-8.
3. Lofgren SM, Bond DJ, Nakasujja N, Boulware DR. Burden of Depression in Outpatient HIV-Infected adults in Sub-Saharan Africa; Systematic Review and Meta-analysis. *AIDS and behavior*. 2020;24(6):1752-64.
4. Chibanda D, Verhey R, Gibson LJ, Munetsi E, Machando D, Rusakaniko S, et al. Validation of screening tools for depression and anxiety disorders in a primary care population with high HIV prevalence in Zimbabwe. *Journal of affective disorders*. 2016;198:50-5.
5. Wagner GJ, Slaughter M, Ghosh-Dastidar B. Depression at Treatment Initiation Predicts HIV Antiretroviral Adherence in Uganda. *Journal of the International Association of Providers of AIDS Care*. 2017;16(1):91-7.
6. Safren SA, Radomsky AS, Otto MW, Salomon E. Predictors of psychological well-being in a diverse sample of HIV-positive patients receiving highly active antiretroviral therapy. *Psychosomatics*. 2002;43(6):478-85.
7. Kidia K, Machando D, Bere T, Macpherson K, Nyamayaro P, Potter L, et al. 'I was thinking too much': experiences of HIV-positive adults with common mental disorders and poor adherence to antiretroviral therapy in Zimbabwe. *Trop Med Int Health*. 2015;20(7):903-13.
8. Kalichman SC, Kalichman MO, Cherry C. Forget about forgetting: structural barriers and severe non-adherence to antiretroviral therapy. *AIDS care*. 2017;29(4):418-22.
9. Wing RR, Phelan S, Tate D. The role of adherence in mediating the relationship between depression and health outcomes. *J Psychosom Res*. 2002;53(4):877-81.
10. UNAIDS. Prevailing against pandemics by putting people at the centre. Geneva; 2020.
11. Abas M, O'Cleirigh C. Global mental health and the ambition to end AIDS by 2030. *The lancet Psychiatry*. 2018;5(11):867-9.
12. Nakimuli-Mpungu E, Musisi S, Smith CM, Von Isenburg M, Akimana B, Shakarishvili A, et al. Mental health interventions for persons living with HIV in low- and middle-income countries: a systematic review. *Journal of the International AIDS Society*. 2021;24(S2):e25722.
13. Sikkema KJ, Dennis AC, Watt MH, Choi KW, Yemeke TT, Joska JA. Improving mental health among people living with HIV: a review of intervention trials in low- and middle-income countries. *Global mental health (Cambridge, England)*. 2015;2:e19.
14. Safren SA, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, et al. Two strategies to increase adherence to HIV antiretroviral medication: Life-Steps and medication monitoring. *Behaviour Research and Therapy*. 2001;39(10):1151-62.
15. Safren SA, Hendriksen ES, Mayer KH, Mimiaga MJ, Pickard R, Otto MW. Cognitive-Behavioral Therapy for HIV Medication Adherence and Depression. *Cognitive and Behavioral Practice*. 2004;11(4):415-24.
16. Safren SA, O'Cleirigh C, Skeer MR, Driskell J, Goshe BM, Covahey C, et al. Demonstration and evaluation of a peer-delivered, individually-tailored, HIV prevention intervention for HIV-infected MSM in their primary care setting. *AIDS Behav*. 2011;15(5):949-58.

17. Safren SA, Bedoya CA, O'Cleirigh C, Biello KB, Pinkston MM, Stein MD, et al. Cognitive behavioural therapy for adherence and depression in patients with HIV: a three-arm randomised controlled trial. *The Lancet HIV*. 2016;3(11):e529-e38.
18. Pence BW, Gaynes BN, Adams JL, Thielman NM, Heine AD, Mugavero MJ, et al. The effect of antidepressant treatment on HIV and depression outcomes: the SLAM DUNC randomized trial. *Aids*. 2015;29(15):1975-86.
19. Andersen LS, Magidson JF, O'Cleirigh C, Remmert JE, Kagee A, Leaver M, et al. A pilot study of a nurse-delivered cognitive behavioral therapy intervention (Ziphamandla) for adherence and depression in HIV in South Africa. *Journal of health psychology*. 2018;23(6):776-87.
20. Abas M, Nyamayaro P, Bere T, Saruchera E, Mothobi N, Simms V, et al. Feasibility and Acceptability of a Task-Shifted Intervention to Enhance Adherence to HIV Medication and Improve Depression in People Living with HIV in Zimbabwe, a Low Income Country in Sub-Saharan Africa. *AIDS Behav*. 2018;22(1):86-101.
21. Nyamayaro P, Bere, T, Magidson, J, Simms, V, O'Cleirigh, C, Chibanda, D, & Abas, MA A task-shifting problem-solving therapy intervention for depression and barriers to antiretroviral adherence for people living with HIV in Zimbabwe. *Cognitive Behavioral Practice*. 2020;27(1):84-92.
22. Jopling R, Nyamayaro P, Andersen LS, Kagee A, Haberer JE, Abas MA. A Cascade of Interventions to Promote Adherence to Antiretroviral Therapy in African Countries. *Current HIV/AIDS Reports*. 2020;17(5):529-46.
23. National Medicines and Therapeutics Policy Advisory Committee (NMTPAC) and The AIDS and TB Directorate Ministry of Health and Child Care Zimbabwe. Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in Zimbabwe. Harare Zimbabwe; 2016.
24. Zimbabwe National Statistics Agency. Mashonaland East Province District Population Projections Report. Harare; 2020.
25. PopulationStat. Chitungwiza Zimbabwe Population 2021 [Available from: <https://populationstat.com/zimbabwe/chitungwiza>].
26. Falkingham J, Namazie C, . Measuring health and poverty: a review of approaches to identifying the poor: Department for International Development Health Systems Resource Centre; 2002.
27. Wambogo EA, Ghattas H, Leonard KL, Sahyoun NR. Validity of the Food Insecurity Experience Scale for Use in Sub-Saharan Africa and Characteristics of Food-Insecure Individuals. *Current Developments in Nutrition*. 2018;2(9).
28. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 1983;67(6):361-70.
29. Jelsma J, Hansen K, De Weerd W, De Cock P, Kind P. How do Zimbabweans value health states? *Population Health Metrics*. 2003;1(1):1.
30. Babor TF, De La Fuente MF, Saunders JB, Grant M. AUDIT - The Alcohol use Disorders Identification Test: Guidelines for use in Primary Health Care. Geneva, Switzerland: World Health Organization; 1989.
31. Hildebrand M. The Psychometric Properties of the Drug Use Disorders Identification Test (DUDIT): A Review of Recent Research. *J Subst Abuse Treat*. 2015;53:52-9.

- 1
2
3 32. Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, et al. The
4 International HIV Dementia Scale: a new rapid screening test for HIV dementia. *Aids*.
5 2005;19(13):1367-74.
6
7 33. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-
8 International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a
9 structured diagnostic psychiatric interview for DSM-IV and ICD-10. *Journal of Clinical*
10 *Psychiatry*. 1998;59 Suppl 20:22-33;quiz 4-57.
11 34. A Szende, B Janssen, J Cabases. In: Szende A, Janssen B, Cabases J, editors. *Self-*
12 *Reported Population Health: An International Perspective based on EQ-5D*. Dordrecht (NL):
13 Springer Copyright 2014, The Editor(s) (if applicable) and the Author(s). 2014.
14
15 35. Mogga S, Prince M, Alem A, Kebede D, Stewart R, Glozier N, et al. Outcome of major
16 depression in Ethiopia: Population-based study. *British Journal of Psychiatry*. 2006;189(3):241-
17 6.
18 36. Wampold BE. How important are the common factors in psychotherapy? An update.
19 *World psychiatry : official journal of the World Psychiatric Association (WPA)*. 2015;14(3):270-
20 7.
21 37. Bere T, Nyamayaro P, Magidson JF, Chibanda D, Chingono A, Munjoma R, et al.
22 Cultural adaptation of a cognitive-behavioural intervention to improve adherence to antiretroviral
23 therapy among people living with HIV/AIDS in Zimbabwe: Nzira Itsva. *Journal of health*
24 *psychology*. 2017;22(10):1265-76.
25 38. D'Zurilla T, Nezu A. Problem-Solving Therapy. In: Keith S. Dobson, editor. *Handbook*
26 *of Cognitive-Behavioral Therapies, Third Edition*. United States of America: The Guilford Press;
27 2010.
28 39. Abas M, Bowers T, Manda E, Cooper S, Machando D, Verhey R, et al. 'Opening up the
29 mind': problem-solving therapy delivered by female lay health workers to improve access to
30 evidence-based care for depression and other common mental disorders through the Friendship
31 Bench Project in Zimbabwe. *International Journal of Mental Health Systems*. 2016;10(1):1-8.
32 40. Chibanda D, Weiss HA, Verhey R, et al. Effect of a primary care-based psychological
33 intervention on symptoms of common mental disorders in zimbabwe: A randomized clinical
34 trial. *JAMA*. 2016;316(24):2618-26.
35 41. Kohrt BA, Jordans MJD, Rai S, Shrestha P, Luitel NP, Ramaiya MK, et al. Therapist
36 competence in global mental health: Development of the ENhancing Assessment of Common
37 Therapeutic factors (ENACT) rating scale. *Behaviour Research and Therapy*. 2015;69:11-21.
38 42. AIDS & TB Programme Ministry of Health and Child Care Zimbabwe. *Operational and*
39 *Service Delivery Manual for the Prevention, Care and Treatment of HIV in Zimbabwe*.
40 Zimbabwe: Ministry of Health and Child Care,; 2017.
41 43. WHO. mhGAP Mental Health Gap Action Programme: Scaling up care for mental,
42 neurological and substance use disorders. Geneva: World Health Organisation; 2010.
43 44. Nau D. Proportion of days covered (PDC) as a preferred method of measuring medication
44 adherence. *Pharm Qual Alliance*. 2012.
45 45. Wilson IB, Lee Y, Michaud J, Fowler FJ, Jr., Rogers WH. Validation of a New Three-
46 Item Self-Report Measure for Medication Adherence. *AIDS Behav*. 2016;20(11):2700-8.
47 46. White IR, Thompson SG. Adjusting for partially missing baseline measurements in
48 randomized trials. *Stat Med*. 2005;24(7):993-1007.
49 47. Dong, Peng. *Principled missing data methods for researchers*: SpringerPlus
50
51
52
53
54
55
56
57
58
59

1
2
3 2013. 2-222 p.

4 48. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.
5 Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *BMJ* :
6 *British Medical Journal*. 2013;346:f1049.

7
8 49. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be
9 analysed? *Bmj*. 2000;320(7243):1197-200.

10 50. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of
11 the non-parametric bootstrap. *Stat Med*. 2000;19(23):3219-36.

12 51. Chibanda D, Cowan F, Gibson L, Weiss HA, Lund C. Prevalence and correlates of
13 probable common mental disorders in a population with high prevalence of HIV in Zimbabwe.
14 *BMC psychiatry*. 2016;16(1):55.

15
16 52. Remien RH, Patel V, Chibanda D, Abas MA. Integrating mental health into HIV
17 prevention and care: a call to action. *Journal of the International AIDS Society*.
18 2021;24(S2):e25748.

19 53. UNAIDS. End Inequalities. End AIDS. Global AIDS strategy 2021-2026. Geneva:
20 UNAIDS; 2020.



Figure 1: Stepped Care-AD Flow

Figure 2: Participant Flow



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	1
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	1
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1-2
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	2
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	14

1 **Introduction**

2

3 Background and 6a Description of research question and justification for undertaking the trial, including summary of relevant 4-5
 4 rationale studies (published and unpublished) examining benefits and harms for each intervention

5

6 6b Explanation for choice of comparators 5

7

8 Objectives 7 Specific objectives or hypotheses 5

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),
 11 allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 5

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 5
 17 be collected. Reference to where list of study sites can be obtained

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 6
 20 individuals who will perform the interventions (eg, surgeons, psychotherapists)

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 8-11, 19
 23 administered

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 8-10
 26 change in response to harms, participant request, or improving/worsening disease)

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 11-13
 29 (eg, drug tablet return, laboratory tests)

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 8-11

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood
 35 pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, 11-12
 36 median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen
 37 efficacy and harm outcomes is strongly recommended

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 7-8, 20
 41 participants. A schematic diagram is highly recommended (see Figure)

42

43

44

45

46

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	14
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	6, 12-13
5				

6 **Methods: Assignment of interventions (for controlled trials)**

7 Allocation:

8				
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	7
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	7
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	7
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	13-14
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	13-14
28				
29				
30				

31 **Methods: Data collection, management, and analysis**

32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	11-12
34	methods			
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	12-13
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12-13
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	15-16
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	16
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	16
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	14
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	13-14
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	12, 14
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	13
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	13
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	6
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	12
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	1
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	13-14
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	3, 6
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	17
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	N/A
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
35				
36				

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](https://creativecommons.org/licenses/by-nc-nd/3.0/) license.

BMJ Open

Task-sharing with lay counsellors to deliver a stepped care intervention to improve depression, antiretroviral therapy adherence, and viral suppression in people living with HIV: study protocol for the TENDAI randomised controlled trial.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057844.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Apr-2022
Complete List of Authors:	Abas, Melanie; King's College London, Section of Epidemiology, Health Services & Population Research Mangezi, Walter; University of Zimbabwe, Department of Primary Health Care Sciences, Unit of Mental Health Nyamayaro, Primrose; University of Zimbabwe, Department of Primary Health Care Sciences, Unit of Mental Health Jopling, Rebecca; King's College London, Health Service & Population Research Department Bere, Tarisai; University of Zimbabwe, Department of Primary Health Care Sciences, Unit of Mental Health McKetchnie, Samantha M.; Massachusetts General Hospital, Psychiatry; The Fenway Institute at Fenway Health Goldsmith, Kimberley; King's College London, Department of Biostatistics & Health Informatics Fitch, Calvin; Massachusetts General Hospital, Department of Psychiatry; Fenway Institute Saruchera, Emily; University of Zimbabwe, Department of Primary Health Care Sciences Muronzie, Thabani; University of Zimbabwe, Department of Primary Health Care Sciences Gudyanga, Denford; University of Zimbabwe, Department of Primary Health Care Sciences Barrett, Barbara; King's College London, Health Service & Population Research Department, Institute Of Psychiatry, Psychology & Neuroscience Chibanda, D; University of Zimbabwe, Department of Psychiatry; London School of Hygiene & Tropical Medicine, Centre for Global Mental Health Hakim, James; University of Zimbabwe Medical School Clinical Research Centre Safren, Steven; University of Miami, O'Cleirigh, Conall; Massachusetts General Hospital, Department of Psychiatry; Fenway Institute
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Mental health

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Depression & mood disorders < PSYCHIATRY, HEALTH ECONOMICS, MENTAL HEALTH, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

Task-sharing with lay counsellors to deliver a stepped care intervention to improve depression, antiretroviral therapy adherence, and viral suppression in people living with HIV: study protocol for the TENDAI randomised controlled trial.

Melanie Abas¹, Walter Mangezi², Primrose Nyamayaro², Rebecca Jopling¹, Tarisai Bere², Samantha M. McKetchnie^{3,4,5}, Kimberley Goldsmith⁶, Calvin Fitch^{3,5,7}, Emily Saruchera², Thabani Muronzie², Denford Gudyanga², Barbara Barrett¹, Dixon Chibanda^{2,8}, James Hakim^{2*}, Steven A. Safren⁹, and Conall O’Cleirigh^{3,5,7}

1. Health Service & Population Research Department, Institute of Psychiatry, Psychology, & Neuroscience, King’s College London, UK
2. Department of Primary Health Care Sciences, Unit of Mental Health, University of Zimbabwe, ZI
3. Behavioral Medicine Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA
4. School of Social Work, Boston College, Newton, Massachusetts, USA
5. The Fenway Institute, Fenway Health, Boston, Massachusetts, USA
6. Department of Biostatistics & Health Informatics, Institute of Psychiatry, Psychology, & Neuroscience, King’s College London, UK
7. Department of Psychiatry, Harvard Medical School, Cambridge, Massachusetts, USA
8. Centre for Global Mental Health, London School of Hygiene and Tropical Medicine, London, UK
9. Center for HIV Research in Mental Health, Department of Psychology, University of Miami, Coral Gables, Florida, USA

Corresponding Author:

Conall O’Cleirigh, Ph.D.
Massachusetts General Hospital
Harvard Medical School
Department of Psychiatry
Boston, MA USA
cocleirigh@mgh.harvard.edu

Trial registration: ClinicalTrials.gov Identifier: NCT04018391

Funding: R01 MH114708 awarded to Prof Abas and Dr O’Cleirigh by the National Institute of Mental Health (NIMH), NIH.

Date and Version: 22 September 2021, version 1.0

Conflicts of Interest: The authors do not have any conflicts of interest to report.

Roles of Contributors

*Professor James Hakim was involved in the TENDAI study and this manuscript up until his death in 2020

1
2
3 **Melanie Abas:** Professor Abas is the King's College London PI for the trial and engaged in
4 substantial writing of this manuscript and gaining funding for the study.

5
6 **Walter Mangezi:** Dr. Mangezi is the University of Zimbabwe PI for the trial and engaged in
7 revision of this manuscript and gaining funding for the study.

8
9 **Primrose Nyamayaro:** Ms. Nyamayaro is the University of Zimbabwe Project Director for the
10 trial and engaged in revision of this manuscript.

11 **Rebecca Jopling:** Ms. Jopling is the King's College London Project Director for the trial and
12 engaged in substantial writing of this manuscript.

13
14 **Tarisai Bere:** Mrs. Bere is the University of Zimbabwe Clinical Supervisor for the trial and
15 engaged in substantial writing of this manuscript.

16
17 **Samantha M. McKetchnie:** Mrs. McKetchnie is the trial Data Manager and engaged in
18 substantial writing of this manuscript.

19 **Kimberley Goldsmith:** Dr. Goldsmith is the Trial Statistician and engaged in substantial writing
20 of this manuscript and gaining funding for the study.

21
22 **Calvin Fitch:** Dr. Fitch is the Massachusetts General Hospital Clinical Supervisor for the trial
23 and engaged in revision of this manuscript.

24
25 **Emily Saruchera:** Mrs. Saruchera is the Senior Research Assistant for this trial and engaged in
26 substantial writing of this manuscript.

27
28 **Thabani Muronzie:** Mr. Muronzie is a Research Assistant for this trial and engaged in
29 substantial writing of this manuscript.

30
31 **Denford Gudyanga:** Mr. Gudyanga is a Research Assistant for this trial and engaged in
32 substantial writing of this manuscript.

33
34 **Barbara Barrett:** Dr. Barrett is the Trial Health Economist and engaged in revision of this
35 manuscript. and gaining funding for the study

36
37 **Dixon Chibanda:** Dr. Chibanda is a Co-Investigator on this trial and provided guidance around
38 the development and execution of this manuscript and gaining funding for the study.

39
40 **James Hakim:** Professor . Hakim was a Co-Investigator on this trial. He assisted in gaining
41 funding for the study and provided guidance around the development and execution of this
42 manuscript up until his untimely death in 2020.

43
44 **Steven A. Safren:** Professor . Safren is a Co-Investigator on this trial and provided guidance
45 around the development and execution of this manuscript and gaining funding for the study.

46
47 **Conall O'Cleirigh:** Dr. O'Cleirigh is the Massachusetts General Hospital PI for the trial and
48 engaged in substantial writing of this manuscript and assisted in gaining funding for the study.

49
50 **Sponsor:** The National Institute of Mental Health provides funding for this trial and monitors
51 progress on the project through yearly Research Performance Progress Reports.

52 Abstract

53 Introduction: Non-adherence to antiretroviral therapy (ART) is the main cause of viral
54 non-suppression and its risk is increased by depression. In countries with high burden of HIV
55
56
57
58
59

1
2
3 there is a lack of trained professionals to deliver depression treatments. This paper describes the
4 protocol for a 2-arm parallel group superiority 1:1 randomised controlled trial, to test the
5 effectiveness and cost-effectiveness of the TENDAI stepped care task-shifted intervention for
6 depression, ART non-adherence, and HIV viral suppression delivered by lay interventionists.
7
8 Methods and Analysis: Two hundred and ninety people living with HIV (PLHIV) aged ≥ 18 years
9
10 with probable depression (Patient Health Questionnaire ≥ 10) and viral non-suppression (\geq
11 1000 HIV copies per ml) are being recruited from HIV clinics in towns in Zimbabwe. The
12 intervention group will receive a culturally adapted 6-session psychological treatment (PST-AD)
13 including problem-solving therapy, positive activity scheduling, skills to cope with stress and
14 poor sleep, and content to target barriers to non-adherence to ART. Participants whose score on
15 the PHQ-9 remains ≥ 10 , and/or falls by less than 5-points, step up to a nurse-evaluation for
16 possible antidepressant medication. The control group receives usual care for viral non-
17 suppression, consisting of three sessions of adherence counselling from existing clinic staff, and
18 enhanced usual care for depression in line with the WHO Mental Health Gap intervention guide.
19 The primary outcome is viral suppression (< 1000 HIV copies per ml) at 12 months post-
20 randomisation. Ethics and Dissemination: The study and its tools were approved by
21 MRCZ/A/2390 in Zimbabwe and RESCM-18/19-5580 in the United Kingdom. Study findings
22 will be shared through the community advisory group, conferences, and open access
23 publications.

24 **Strengths and Limitations:**

25 **Strengths:**

- 26 • The first randomised controlled trial in a low-income country to test an intervention to
27 improve both adherence to antiretroviral therapy and depression in people living with
28 HIV.
- 29 • Culturally adapted and culturally appropriate intervention to address barriers to adherence
30 to antiretroviral therapy and to treat depression, based on extensive preliminary work.

- Assessment of the cost-effectiveness of the TENDAI stepped care task-shifted intervention
- Stepped care intervention is delivered through task-shifting to non-specialist staff, allowing for future scale up.

Limitation:

- Limited scope to assess implementation science questions given the individually randomised design.

Introduction

Over 27% of people in sub-Saharan Africa currently receiving antiretroviral therapy (ART) are non-adherent (1), and non-adherence to ART is the main cause of viral non-suppression (2). Achieving and maintain viral suppression is not only an effective HIV treatment strategy but also an effective HIV prevention approach, preventing transmission of the virus to sexual partners, and from mother to child (3, 4). Depression is among the strongest correlates of non-adherence and affects over 15% of PLHIV attending HIV out-patient clinics in sub-Saharan Africa (1, 5, 6). Depression is linked to non-adherence through the reduced motivation and forgetting to take ART (7), through impaired problem-solving ability (8), and may interfere with uptake of existing adherence support programs. Depression may also impact adherence through its association with structural factors, such as poverty, and interpersonal difficulties which impede access to HIV medication (7, 9, 10). Non-adherence to ART may also precede and increase risk of depression (11). Evidence-based interventions for depression include psychological interventions based on cognitive behavioural approaches, and antidepressant medication (12)

Countries with high burden of HIV, such as Zimbabwe, have a dearth of trained mental health professionals. Given the public health importance of viral suppression (13), and the strong association with depression, adherence interventions must address comorbid psychological factors and be able to be delivered through task-shifting to non-specialists (14). Systematic reviews of mental health interventions in PLHIV in low resource settings have been unable to

1
2
3 report effects on HIV outcomes as, to date, these have not been studied (15, 16).
4

5
6 The most promising evidence for the effectiveness and utility of integrated treatments for
7
8 depression and ART adherence for PLHIV has come from the development of Cognitive
9
10 Behavioural Therapy for Adherence and Depression (CBT-AD) in the United States (17, 18).
11
12 CBT-AD, which includes the “Life Steps” intervention for addressing barriers to medication
13
14 adherence, has been shown to improve rates of ART adherence, and to reduce depression
15
16 severity among men in the US (19, 20). In contrast, interventions for PLWH with depression
17
18 and poor adherence which *only* target mood have not been found to improve viral suppression
19
20 (21). Recent reports, including from our team in Zimbabwe, support the acceptability and
21
22 feasibility of culturally-adapted cognitive behavioural interventions for low resource settings
23
24 (22-24). However, there have yet to be any definitive RCTs from low resource settings focused
25
26 on treatment of depression and ART adherence to improve viral suppression (25). Thirteen
27
28 percent of the adult population in Zimbabwe is living with HIV, with 22% of those virally non-
29
30 suppressed (22). The objective of this trial is to test the effectiveness and cost-effectiveness of
31
32 the TENDAI stepped care psychological intervention for adherence to ART and depression,
33
34 (Stepped Care-AD), compared to enhanced usual care, for PLHIV in Zimbabwe with viral non-
35
36 suppression and depression. TENDAI is derived from principles of problem-solving and
37
38 psychoeducation for depression and adherence, and motivational interviewing.
39
40
41
42
43

44 **Methods and Analysis**

45 **Study Design and Setting**

46
47 The study is a two-arm parallel group superiority 1:1 randomised effectiveness trial
48
49 (n=290). PLHIV receive care according to the standard national guidelines (26). Viral load is
50
51 monitored every 12 months, with more frequent screening every 3 months for those who are
52
53
54
55
56
57
58
59
60

1
2
3 virally non-suppressed. Participants are being recruited from two sites in Zimbabwe providing
4 HIV services for those initiated on ART. These are the Marondera Provincial Hospital, and
5
6 Chitungwiza Central Hospital, along with satellite clinics for each hospital. Marondera is the
7
8 capital of Mashonaland East province, situated in the north east of Zimbabwe. The town and its
9
10 surrounding district have a total population of approximately 224,000 (27). Chitungwiza is an
11
12 urban town, divided into five townships, with a total population of approximately 391,000 (28).
13
14 Taken together, both sites combined have approximately 25,000 adults registered as receiving
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Patient and Public Involvement

No patient involvement in the design of the study. Results will be disseminated to study participants and community members via local advisory groups.

Eligibility Criteria

Inclusion criteria: 1) HIV positive and initiated on ART for at least 6 months; 2) clinically significant depression symptoms (operationalised as a score of 10 or more on the locally validated Patient Health Questionnaire (PHQ-9) (6); 3) virally non-suppressed in the past 2 months (viral load \geq 1000 copies/mL); 4) able to provide informed consent ; and 5) if prescribed anti-depressants, have been on a stable anti-depressant regimen for at least 2 months.

Exclusion criteria: 1) unwilling or unable to provide informed consent; 2) major untreated or undertreated mental illness (e.g. untreated psychosis or mania, actively suicidal assessed using the MINI and P4 suicide screener), major or advanced physical disease (assessed using clinic records) or severe cognitive impairment (assessed using the International HIV dementia scale) which would interfere with engagement in Stepped Care-AD; 3) have received a course of

1
2
3 problem solving therapy or cognitive-behavioural psychological therapy for depression; or 4)
4
5 <18 years old.
6

7 8 **Study Procedures**

9 10 **Recruitment and Informed Consent**

11
12 See Figure 1 for study flow. Research Assistants (RAs) in the ART clinic approach
13
14 patients identified by clinic staff as having a detectable viral load (>1000 copies/mL) in the past
15
16 2 months or at high risk of viral non-suppression, e.g., self-reported poor adherence. Potentially
17
18 eligible individuals will complete a brief screen for inclusion and exclusion criteria. Those
19
20 meeting initial screening eligibility criteria are invited to complete informed consent procedures
21
22 and the full baseline assessment. Informed consent will include consent to access participants'
23
24 medical records, and for telephone calls and home visits if needed for follow-up. Capacity to
25
26 provide consent is assessed by a licensed psychiatrist (WM) for any participant indicating
27
28 consent but suspected of being unable to fully understand and/or retain information provided.
29
30
31

32 33 **Baseline**

34
35 A trained RA collects data by face-to-face interview including: demographics, measures
36
37 of socio-economic position (employment status, educational history, and ownership of household
38
39 assets) (29, 30), depression using the Patient Health Questionnaire (PHQ-9) (6), anxiety using
40
41 the Hospital Anxiety and Depression Scale (31) quality of life using The EQ-5D-3L (32), use of
42
43 alcohol and substances (33, 34), cognitive impairment using the International HIV Dementia
44
45 Scale (35), psychiatric diagnosis using the MINI International Neuropsychiatric Interview (36),
46
47 use of health services in the last 4 months using a modified version of the Client Services
48
49 Receipt Inventory (31) and several additional exploratory measures.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Viral load in the past 60 days is ascertained from the participants medical records, or, for
4 those who have not been tested in the past two months, by testing plasma. Current ART regimen
5 and recent CD4 test results are taken from participants medical records. A blood sample for dried
6 blood spot (DBS) is used to detect the presence of ART medications (37).
7
8
9

12 **Eligibility**

14 The study team, including a clinical psychologist or psychiatrist, will meet weekly via
15 teleconference to discuss each baseline assessment and confirm that participants meet eligibility
16 criteria.
17
18
19

22 **Randomisation**

24 Approximately 2 weeks after the baseline assessment, eligible participants return for a
25 randomisation visit and are randomly assigned to Stepped Care-AD or enhanced usual care
26 (EUC). Randomisation is determined by a computer-generated chart and is conducted via the
27 REDCap randomisation module by the Zimbabwe site Programme Manager.
28
29
30

33 **Follow-Up Assessments**

35 In addition to baseline, there are 3 major study assessments: 4-, 8-, and 12-months post-
36 randomisation. An Independent Assessor (IA) who is blind to study condition will administer the
37 PHQ-9, EQ-5D-3L, and self-report medication adherence measures. RAs will collect self-report
38 data including use of alcohol and substances (33, 34), Hospital Anxiety and Depression Scale for
39 Anxiety (31), quality of life (32), and use of other health care services (38) . At the final 12-
40 month follow-up, we will also extract chart information from medical records for pharmacy refill
41 data and HIV viral load results. Participants without a viral load test in the past 30 days are
42 invited to undergo venepuncture for viral load testing, which is in addition to the venepuncture
43 for ART detection.
44
45
46
47
48
49
50
51
52
53
54

Interventions

Active Intervention Arm: Task-sharing Stepped Care Intervention for Adherence and Depression (TENDAI Stepped Care-AD).

As shown in Figure 2, all participants in the TENDAI arm receive six 50-minute sessions of a culturally adapted intervention for depression and non-adherence to ART delivered weekly, followed by one booster session six weeks later. The intervention is based on cognitive behavioural principles and includes problem-solving therapy, positive activity scheduling, skills to cope with stress and poor sleep, and content to target barriers to non-adherence to ART. Training of interventionists delivered by expert clinicians emphasises common elements of effective psychological interventions including empathy, active listening, and creating realistic hope (39).

A) Adherence to antiretroviral therapy. Session 1 comprises a locally adapted version of the Lifesteps adherence intervention called *Nzira Itsva* (17, 40). This includes motivation, goal setting, video-based education and problem solving. Motivational interviewing is used to identify the participants' life goals and to tie adherence to achieving these goals. Education about on time adherence is provided using an animated video in the Shona language. Barriers to adherence are assessed through a culturally adapted checklist. During each of the subsequent sessions 2-6 targeting depression, 5- to 10-minute adherence boosters are included to review adherence to ART and the participants' experience with strategies to overcome barriers to adherence.

B) Psychological intervention for depression. Sessions 2 and 3 focus on psychoeducation about depression and problem-solving therapy (PST) (41), incorporating storytelling and illustrations, and training in problem-solving. A goal for each session is to identify a defined specific problem to work on, to collaboratively agree a solution to work on and to schedule

1
2
3 homework. An intervention based on PST has been shown to be acceptable and effective for
4 depression in Zimbabwe (42, 43). In Session 4 participants are encouraged to choose and
5 schedule at least four adaptive activities in which to engage: an activity that promotes a sense of
6 achievement, a physical activity, a pleasurable activity, and a social activity. Homework is
7 mutually agreed as part of every session, to test out participants' implementation of solutions to
8 problems, and of positive activities. Thorough review of homework is done at each session,
9 including barriers to doing homework. Skills to promote good sleep and relaxation are taught in
10 Sessions 5 and 6. A relapse prevention plan is developed in session 6 including triggers for
11 relapse of depression, warning signs, coping strategies and self-care activities. Fidelity of the
12 intervention will be assessed through rating 10% of audio-recorded sessions for adherence to the
13 intervention protocol and for therapist competence (44).

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
C) Booster session. About six weeks after the sixth session, participants are invited to a
50-minute booster session. This includes a review of depressive symptoms, and of adherence to
HIV treatment and, where appropriate, adherence to antidepressant medication. The session
includes ongoing positive activity scheduling to promote recovery from depressive symptoms.

D) Stepped up care. Participants with persistent depression (depression score continuing
above cut-off (PHQ-9 ≥ 10) or if they have less than a 5-point improvement in PHQ-9 score)
after at least 4 sessions receive step up to a nurse-evaluation for antidepressant medication. The
antidepressant Fluoxetine is offered for those with confirmed depression.

Control Arm: Enhanced Usual Care (EUC)

All participants in the control arm receive Enhanced Usual Care (EUC) comprising usual
care for viral non-suppression, and enhanced usual care for depression in line with the WHO
Mental Health Gap intervention guide. Usual care for those with viral non-suppression includes

1
2
3 three sessions of adherence counselling provided by an adherence counsellor, nurse, or NGO
4 support worker based at the clinic. These sessions include establishing the participants
5 knowledge about HIV and ART, providing information about use of ART, encouraging
6 adherence, and describing barriers to adherence. Strategies commonly used include encouraging
7 use of an alarm and a treatment supporter, linking ART taking to daily routines, and disclosure of
8 HIV status. The first session is given on the day of receiving viral load results, with two
9 subsequent sessions scheduled on a monthly basis. Referrals may be made to local support
10 groups or organisations for social or economic support, general psychological support or to an
11 HIV clinician. The HIV operational strategy recommends that all patients living with HIV and
12 registered at facility should be screened for common mental disorders (CMD) annually. Patients
13 with high viral load or those initiating ART should be screened for CMD at their appointment
14 (45). Patients exhibiting symptoms of common mental disorders or psychological distress should
15 be managed with counselling interventions and are usually referred to the outpatient's
16 department to be assessed by a Psychiatric nurse. If they require further treatment, they will be
17 seen by a psychiatrist. Patients can also be referred to community-based organization to receive
18 psychosocial services (45). Usual care for depression is enhanced in three ways: 1) The study
19 team will train all health service providers in the study sites on psychological and antidepressant
20 management of depression using the WHO Mental Health Gap intervention guide (mhGAP)
21 (46); 2) we will provide a letter for each participant communicating the patients PHQ-9 score
22 and probable depression to their HIV-care provider; and 3) we will provide those in the EUC
23 condition with access to Stepped Care-AD upon completion of their 12-month follow-up visit.

51 Outcomes

54 Primary Outcome

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Viral suppression at 12-months post-randomisation follow-up (defined as <1000 copies/mL), measured through blood (plasma). This measure will be taken from the medical record if viral load was collected within 30 days of the expected visit date or through study specific assay if not in the medical record.

Secondary Outcomes

1. Depression at 12 months post randomisation measured as the total score on the Patient Health Questionnaire (PHQ-9) (6).
2. Adherence to ART medication at 4-, 8-, and 12-months post randomisation assessed as the proportion of the sample achieving at least 90% adherence in the past month assessed through pharmacy refill (47).
3. Self-reported adherence to ART medication at 4-, 8-, and 12-months post randomisation assessed as the frequency of adherence in the past 30 days measured using a score derived from a three-item questionnaire adapted from Wilson et al. (2015)(48).
4. Viral load copies/mL at 12-months post-randomisation follow-up measured as mean log Viral Load.

Tertiary Outcomes

The total costs of the health care services used by each study participant will be calculated using service use information collected from hospital records and from participant self-report (via a modified version of the Client Services Receipt Inventory suitable for use in sub-Saharan Africa (38)) at 4-, 8-, and 12-month follow-up and with unit costs identified and calculated using locally available data. Detailed information on the use of Stepped Care-AD and EUC will be collected from therapist records. Quality of life at 4, 8 and 12 months is measured

1
2
3 using EQ-5D-3L (32). Quality-adjusted life years will be calculated using Zimbabwe-specific
4 health states (37).
5
6

7 **Data Collection and Management**

8
9
10 Trial data is collected and stored in REDCap, a data management tool designed for
11 collection and protection of patient health information. The REDCap database is hosted and
12 routinely audited at Massachusetts General Hospital (MGH), with access restricted via user roles.
13
14 Data extracts are sent to the study statisticians, via secure file transfer. To ensure accuracy of
15 collected data, MGH staff generate weekly error reports. These error reports are then sent to staff
16
17 in Zimbabwe, who correct any discrepancies and document changes made to the database.
18
19
20
21
22

23 **Strategies to Improve Participant Retention**

24
25
26 Procedures to maximise participant retention include reimbursing participants for
27 attending study visits (equal amount in both arms), sending text message reminders before
28 scheduled appointments and collection of locator information (e.g., contact information of two
29 significant others with whom the participant is in regular contact). We will make efforts to retain
30 individuals who move to a non-study site for their HIV care and are willing to complete follow-
31 up. Where participants are unable to travel to the clinic to complete follow up assessments (e.g.
32 because of COVID-19 lockdown travel restriction), participants will be offered phone
33 assessments. Where participants can not be reached by phone, a home visit may be conducted.
34
35
36
37
38
39
40
41
42
43

44 **Ethics**

45
46
47 All study procedures were reviewed and approved by ethics committees at King's
48 College London (RESCM-17/18-5580), Massachusetts General Hospital (IRB00012706), and
49 the Medical Research Council of Zimbabwe (MRCZ/A/2390). Serious adverse events (SAEs)
50
51
52
53
54
55
56
57
58
59
60

1
2
3 will be reported to research ethics committees at King's College London, MGH, and the Medical
4
5 Research Council of Zimbabwe within 72 hours.
6

7 **Confidentiality**

8
9
10 Participants are given a study-specific identification number at screening that is used on
11
12 all forms and data collection instruments, excluding the consent form. Participants are referred to
13
14 only by their identification number during eligibility and supervision meetings. A file that links
15
16 participant names to identification numbers is stored in a locked file at the University of
17
18 Zimbabwe.
19
20

21 **Blinding**

22
23
24 To reduce bias and maximise the validity of the findings, the Independent Assessor (IA)
25
26 for the primary and secondary outcomes, and the lead study statistician, are blinded to
27
28 randomisation condition. To ensure blinding, the IA will explain their role to participants and ask
29
30 that they do not give the IA information about the treatment they received. The lead study
31
32 statistician will not attend meetings where randomisation or clinical issues are discussed, and
33
34 their access in REDCap is restricted so that they cannot view any data or report that may unblind
35
36 them. A second statistician, who will conduct the analyses and will review data for thoroughness
37
38 and completeness, will not be blinded. This trial does not have procedures for unblinding IAs or
39
40 the lead study statistician. If the IA is concerned about the safety of a participant, they will
41
42 communicate the concern to study staff, who will contact the clinical supervisor.
43
44
45

46 **Data Safety and Monitoring Board (DSMB)**

47
48
49 A DSMB, consisting of members with experience in clinical trials for mental disorders,
50
51 biostatistics, HIV in African settings, and human subject protection issues will function
52
53 independent of the sponsor and monitor safety of study participants and integrity of data. The
54
55
56
57
58
59

1
2
3 DSMB will meet annually and receive safety information in an unblinded manner. Expedited
4 review by the DSMB will occur for all serious adverse events (SAE) as defined as any fatal,
5 immediately life-threatening, or substantially disabling event; event requiring or prolonging
6 inpatient hospitalisation, or any congenital anomaly.
7
8
9
10

11 **Statistical Methods**

12 **Sample Size**

13
14
15 Using two-sided Fisher's exact test, $\alpha = 0.05$ and 20% attrition, a sample size of 290
16 participants will provide 85% power to detect an absolute difference of 20% or more in
17 achieving viral suppression (e.g. 45% in the EUC arm vs. 65% in the intervention arm) at 12-
18 months follow-up. Pilot data showed a larger difference between arms (50% in the EUC arm vs.
19 75% in the intervention arm) (23), suggesting this should be a conservative sample size estimate.
20
21
22
23
24
25
26
27

28 **Statistical Methods for Primary and Secondary Outcomes**

29
30
31 Baseline and outcome variables will be summarised using appropriate statistics; no
32 baseline statistical comparisons will be made. The main analysis will follow intention to treat
33 principles, reporting appropriate 95% confidence intervals and use a 5% significance level. All
34 models will include a site stratification variable. In the mixed models we will have random
35 intercepts at the participant level, and random slopes if warranted (assessed via likelihood ratio
36 test).
37
38
39
40
41
42
43

44
45 Twelve-month primary outcome viral load will be coded as suppressed (<1000
46 copies/mL) vs not suppressed (≥ 1000 copies/mL). Where these data are missing, the individual
47 has died, and medical or death records indicate death due to high viral load/death was AIDS
48 related, they will be coded as not suppressed, otherwise the outcome will be left missing.
49
50
51
52
53
54 Suppressed/not suppressed will be the dependent variable in a logistic regression model
55
56
57
58
59
60

1
2
3 estimating the TENDAI vs EUC odds ratio (OR), with trial arm as the independent variable. The
4 mean difference in PHQ-9 depression and self-report adherence will each be estimated using a
5 linear mixed effects model with the 4-, 8- and 12-month measures as dependent variables, with
6 the baseline measure of the outcome, time, and trial arm by time interaction terms as independent
7 variables. The OR at 4, 8 and 12 months for $\geq 90\%$ adherence vs $< 90\%$ adherence by pharmacy
8 refill in the past 30 days will be estimated using a logistic mixed effects model with the 4, 8 and
9 12-month measures as dependent variables, and independent variables as described for PHQ-9
10 and self-report adherence. The mean difference in log copies/mL of viral load at 12 months will
11 be estimated using a linear regression model with log viral load at 12 months as the dependent
12 variable, trial arm and baseline log viral load as independent variables.
13
14
15
16
17
18
19
20
21
22
23
24
25

26 A “per protocol” analysis for the primary viral load outcome only will exclude
27 participants not completing at least four TENDAI sessions, and anyone found to be ineligible
28 post randomisation. No interim or formal powered subgroup analyses are planned, however, we
29 will explore moderation by gender for viral suppression, self-report adherence and depression
30 outcomes by adding a sex by trial arm (by time, where appropriate) interaction term to the final
31 outcome analysis models. Additional exploratory mediation analysis (e.g., to examine changes in
32 both depression and adherence as mediators of treatment related changes in viral load) is
33 planned, but will not be reported on in the main paper. Missing baseline measures will be
34 imputed using simple mean imputation (49). Missing repeatedly measured outcome data will be
35 handled using mixed models/maximum likelihood methods, including baseline variables
36 predicting missing outcome data. If there is more than 10% missing primary outcome data and
37 post-randomisation variables (completion of therapy in the TENDAI arm only and ART
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 adherence at 12 months) predict whether these data are missing, we will consider multiple
4
5 imputation (MI) (50).
6

7
8 Cost-effectiveness results will be reported following CHEERS guidelines (51). Economic
9
10 evaluations can be used to inform healthcare decision makers on the total budget needed to treat
11
12 people with a particular disease or condition; it is only the mean cost that allows for this
13
14 calculation to be made. Thus, it is the arithmetic mean cost that is the relevant summary statistic
15
16 in pragmatic trials with economic evaluations and the mean average total cost in each
17
18 randomised group will be calculated and compared between the two groups using standard t-
19
20 tests, despite the likely skewed nature of the data (52). As is common in the analysis of cost data,
21
22 the robustness of the mean cost comparisons will be confirmed through the calculation of
23
24 nonparametric bootstrapped confidence intervals (53). The primary cost-effectiveness will
25
26 consider costs together with the dichotomous primary outcome measure (viral suppression <1000
27
28 copies/mL), generating information on the incremental cost per successful case (in the form of an
29
30 incremental cost-effectiveness ratio) and the probability that the TENDAI is cost-effective
31
32 compared to enhanced usual care given available information. A secondary cost-utility analysis
33
34 will also be completed, which will report the cost per QALY of the TENDAI intervention
35
36 compared to enhanced usual care via incremental cost-effectiveness ratios. Analyses will be
37
38 adjusted for costs and outcomes. Sensitivity analyses will be carried out to test the robustness of
39
40 costing assumptions to variation.
41
42
43
44
45

46 47 **Dissemination**

48
49 Dissemination of findings will involve three primary papers describing the study
50
51
52
53 outcomes, as well as submitting to lead workshops on the treatment approach at relevant national
54
55
56
57
58
59
60

1
2
3
4 meetings and conferences. Additionally, data will be available to external parties after
5
6
7 publication of the outcome papers via PI-approved application. Data will be stored indefinitely.
8
9

10 **Discussion**

11
12
13 In Zimbabwe, both HIV and co-morbid depression are common, yet, as in other low-
14
15 resource settings with high HIV burden, there is a lack of evidence on interventions to improve
16
17 both ART adherence and depression (54). Due to resource limitations, interventions that allow
18
19 for task-shifting and administration by community health workers are particularly well-placed to
20
21 be effective and sustainable. Our treatment, Stepped Care-AD, blends active ingredients of
22
23 treatment for depression with a culturally-adapted LifeSteps intervention to enhance adherence
24
25 to ART (23, 40). If successful, the Stepped Care-AD intervention represents a useful model for
26
27 policy and for further research. As the primary outcome of the trial is viral suppression, its
28
29 implementation in Zimbabwe and other low-resource settings may further the UNAIDS goal of
30
31 ending the AIDS epidemic by 2030, through optimising viral suppression (55). Results gathered
32
33 in a Zimbabwean context may be leveraged for testing and implementation of similar task-
34
35 shifted stepped care interventions in other Sub-Saharan African settings.
36
37
38
39
40
41

42 **Trial Status**

43
44 This trial began recruitment and enrolment on 2nd July 2019.
45
46

47 **Acknowledgements**

48
49 Mercy Mundwa, Oline Chivere, Sheila Marezva, Vimbai Gwata, Rumbidzai Nyanda,
50
51 Moreblessing Phiri, Megan R. Wirtz, Rachel Holland, Dr Tsitsi Apollo, Dr Celestino Dhege, Dr
52
53 Michael Chiwanga, Tinashe Macheke, and Isaac Masarira,
54
55
56
57
58
59
60

1
2
3 KG contributions to this paper represent independent research part funded by the NIHR
4 Biomedical Research Centre (South London and Maudsley NHS Foundation Trust and KCL) and
5 the NIHR Applied Research Collaboration South London (King's College Hospital NHS
6 Foundation Trust). The views expressed are those of the author(s) and not necessarily those of
7 the NHS, the NIHR or the Department of Health and Social Care.
8
9
10
11
12
13

14 This work is funded by National Institute of Mental Health. Grant number: 1R01MH114708
15
16
17

18 **Figure Legend**

19
20 Figure 1. Flow of Participants through TENDAI Study.
21 Figure 2. Stepped Care-AD Intervention Flow Diagram.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Heestermans T, Browne JL, Aitken SC, Vervoort SC, Klipstein-Grobusch K. Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review. *BMJ Glob Health*. 2016;1(4):e000125.
2. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. *J Infect Dis*. 2008;197 Suppl 3:S272-8.
3. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011;365(6):493-505.
4. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. *J Acquir Immune Defic Syndr*. 2002;29(5):484-94.
5. Lofgren SM, Bond DJ, Nakasujja N, Boulware DR. Burden of Depression in Outpatient HIV-Infected adults in Sub-Saharan Africa; Systematic Review and Meta-analysis. *AIDS and behavior*. 2020;24(6):1752-64.
6. Chibanda D, Verhey R, Gibson LJ, Munetsi E, Machando D, Rusakaniko S, et al. Validation of screening tools for depression and anxiety disorders in a primary care population with high HIV prevalence in Zimbabwe. *Journal of affective disorders*. 2016;198:50-5.
7. Wagner GJ, Slaughter M, Ghosh-Dastidar B. Depression at Treatment Initiation Predicts HIV Antiretroviral Adherence in Uganda. *Journal of the International Association of Providers of AIDS Care*. 2017;16(1):91-7.
8. Safren SA, Radomsky AS, Otto MW, Salomon E. Predictors of psychological well-being in a diverse sample of HIV-positive patients receiving highly active antiretroviral therapy. *Psychosomatics*. 2002;43(6):478-85.
9. Kidia K, Machando D, Bere T, Macpherson K, Nyamayaro P, Potter L, et al. 'I was thinking too much': experiences of HIV-positive adults with common mental disorders and poor adherence to antiretroviral therapy in Zimbabwe. *Trop Med Int Health*. 2015;20(7):903-13.
10. Kalichman SC, Kalichman MO, Cherry C. Forget about forgetting: structural barriers and severe non-adherence to antiretroviral therapy. *AIDS care*. 2017;29(4):418-22.
11. Wing RR, Phelan S, Tate D. The role of adherence in mediating the relationship between depression and health outcomes. *J Psychosom Res*. 2002;53(4):877-81.
12. Abas MA. Combining active ingredients to treat depression in the wake of COVID-19. *The Lancet Psychiatry*. 2022;9(3):190-1.
13. UNAIDS. Prevailing against pandemics by putting people at the centre. Geneva; 2020.
14. Abas M, O'Cleirigh C. Global mental health and the ambition to end AIDS by 2030. *The Lancet Psychiatry*. 2018;5(11):867-9.
15. Nakimuli-Mpungu E, Musisi S, Smith CM, Von Isenburg M, Akimana B, Shakarishvili A, et al. Mental health interventions for persons living with HIV in low- and middle-income countries: a systematic review. *Journal of the International AIDS Society*. 2021;24(S2):e25722.
16. Sikkema KJ, Dennis AC, Watt MH, Choi KW, Yemeke TT, Joska JA. Improving mental health among people living with HIV: a review of intervention trials in low- and middle-income countries. *Glob Ment Health (Camb)*. 2015;2:e19.
17. Safren SA, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, et al. Two strategies to increase adherence to HIV antiretroviral medication: Life-Steps and medication monitoring. *Behaviour Research and Therapy*. 2001;39(10):1151-62.
18. Safren SA, Hendriksen ES, Mayer KH, Mimiaga MJ, Pickard R, Otto MW. Cognitive-Behavioral Therapy for HIV Medication Adherence and Depression. *Cognitive and Behavioral Practice*. 2004;11(4):415-24.

19. Safren SA, O'Cleirigh C, Skeer MR, Driskell J, Goshe BM, Covahey C, et al. Demonstration and evaluation of a peer-delivered, individually-tailored, HIV prevention intervention for HIV-infected MSM in their primary care setting. *AIDS Behav.* 2011;15(5):949-58.
20. Safren SA, Bedoya CA, O'Cleirigh C, Biello KB, Pinkston MM, Stein MD, et al. Cognitive behavioural therapy for adherence and depression in patients with HIV: a three-arm randomised controlled trial. *The Lancet HIV.* 2016;3(11):e529-e38.
21. Pence BW, Gaynes BN, Adams JL, Thielman NM, Heine AD, Mugavero MJ, et al. The effect of antidepressant treatment on HIV and depression outcomes: the SLAM DUNC randomized trial. *Aids.* 2015;29(15):1975-86.
22. Andersen LS, Magidson JF, O'Cleirigh C, Remmert JE, Kagee A, Leaver M, et al. A pilot study of a nurse-delivered cognitive behavioral therapy intervention (Ziphamandla) for adherence and depression in HIV in South Africa. *J Health Psychol.* 2018;23(6):776-87.
23. Abas M, Nyamayaro P, Bere T, Saruchera E, Mothobi N, Simms V, et al. Feasibility and Acceptability of a Task-Shifted Intervention to Enhance Adherence to HIV Medication and Improve Depression in People Living with HIV in Zimbabwe, a Low Income Country in Sub-Saharan Africa. *AIDS Behav.* 2018;22(1):86-101.
24. Nyamayaro P, Bere T, Magidson J, Simms V, O'Cleirigh C, Chibanda D, & Abas, MA A task-shifted intervention for depression integrated with counselling for antiretroviral therapy adherence for people living with HIV/AIDS in Zimbabwe. *Cognitive and Behavioral Practice*; 2020.
25. Jopling R, Nyamayaro P, Andersen LS, Kagee A, Haberer JE, Abas MA. A Cascade of Interventions to Promote Adherence to Antiretroviral Therapy in African Countries. *Current HIV/AIDS Reports.* 2020;17(5):529-46.
26. National Medicines and Therapeutics Policy Advisory Committee (NMT PAC) and The AIDS and TB Directorate Ministry of Health and Child Care Zimbabwe. Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in Zimbabwe. Harare Zimbabwe; 2016.
27. Zimbabwe National Statistics Agency. Mashonaland East Province District Population Projections Report. Harare; 2020.
28. PopulationStat. Chitungwiza Zimbabwe Population 2021 [Available from: <https://populationstat.com/zimbabwe/chitungwiza>].
29. Falkingham J, Namazie C, . Measuring health and poverty: a review of approaches to identifying the poor: Department for International Development Health Systems Resource Centre; 2002.
30. Wambogo EA, Ghattas H, Leonard KL, Sahyoun NR. Validity of the Food Insecurity Experience Scale for Use in Sub-Saharan Africa and Characteristics of Food-Insecure Individuals. *Current Developments in Nutrition.* 2018;2(9).
31. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.* 1983;67(6):361-70.
32. Jelsma J, Hansen K, De Weerd W, De Cock P, Kind P. How do Zimbabweans value health states? *Population Health Metrics.* 2003;1(1):1.
33. Babor TF, De La Fuente MF, Saunders JB, Grant M. AUDIT - The Alcohol use Disorders Identification Test: Guidelines for use in Primary Health Care. Geneva, Switzerland: World Health Organization; 1989.
34. Hildebrand M. The Psychometric Properties of the Drug Use Disorders Identification Test (DUDIT): A Review of Recent Research. *J Subst Abuse Treat.* 2015;53:52-9.
35. Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. *Aids.* 2005;19(13):1367-74.
36. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured

1
2
3 diagnostic psychiatric interview for DSM-IV and ICD-10. *Journal of Clinical Psychiatry*. 1998;59 Suppl
4 20:22-33;quiz 4-57.

5 37. A Szende, B Janssen, J Cabases. In: Szende A, Janssen B, Cabases J, editors. *Self-Reported*
6 *Population Health: An International Perspective based on EQ-5D*. Dordrecht (NL): Springer
7

8 Copyright 2014, The Editor(s) (if applicable) and the Author(s). 2014.

9 38. Mogga S, Prince M, Alem A, Kebede D, Stewart R, Glozier N, et al. Outcome of major depression
10 in Ethiopia: Population-based study. *British Journal of Psychiatry*. 2006;189(3):241-6.

11 39. Wampold BE. How important are the common factors in psychotherapy? An update. *World*
12 *psychiatry : official journal of the World Psychiatric Association (WPA)*. 2015;14(3):270-7.

13 40. Bere T, Nyamayaro P, Magidson JF, Chibanda D, Chingono A, Munjoma R, et al. Cultural
14 adaptation of a cognitive-behavioural intervention to improve adherence to antiretroviral therapy
15 among people living with HIV/AIDS in Zimbabwe: Nzira Itsva. *Journal of Health Psychology*.
16 2017;22(10):1265-76.

17 41. D'Zurilla T, Nezu A. Problem-Solving Therapy. In: Keith S. Dobson, editor. *Handbook of Cognitive-*
18 *Behavioral Therapies, Third Edition*. United States of America: The Guilford Press; 2010.

19 42. Abas M, Bowers T, Manda E, Cooper S, Machando D, Verhey R, et al. 'Opening up the mind':
20 problem-solving therapy delivered by female lay health workers to improve access to evidence-based
21 care for depression and other common mental disorders through the Friendship Bench Project in
22 Zimbabwe. *International Journal of Mental Health Systems*. 2016;10(1):1-8.

23 43. Chibanda D, Weiss HA, Verhey R, et al. Effect of a primary care-based psychological intervention
24 on symptoms of common mental disorders in zimbabwe: A randomized clinical trial. *JAMA*.
25 2016;316(24):2618-26.

26 44. Kohrt BA, Jordans MJD, Rai S, Shrestha P, Luitel NP, Ramaiya MK, et al. Therapist competence in
27 global mental health: Development of the ENhancing Assessment of Common Therapeutic factors
28 (ENACT) rating scale. *Behaviour Research and Therapy*. 2015;69:11-21.

29 45. AIDS & TB Programme Ministry of Health and Child Care Zimbabwe. *Operational and Service*
30 *Delivery Manual for the Prevention, Care and Treatment of HIV in Zimbabwe*. Zimbabwe: Ministry of
31 Health and Child Care;; 2017.

32 46. WHO. mhGAP Mental Health Gap Action Programme: Scaling up care for mental, neurological
33 and substance use disorders. Geneva: World Health Organisation; 2010.

34 47. Nau D. Proportion of days covered (PDC) as a preferred method of measuring medication
35 adherence. *Pharm Qual Alliance*. 2012.

36 48. Wilson IB, Lee Y, Michaud J, Fowler FJ, Jr., Rogers WH. Validation of a New Three-Item Self-
37 Report Measure for Medication Adherence. *AIDS Behav*. 2016;20(11):2700-8.

38 49. White IR, Thompson SG. Adjusting for partially missing baseline measurements in randomized
39 trials. *Stat Med*. 2005;24(7):993-1007.

40 50. Dong, Peng. *Principled missing data methods for researchers*: SpringerPlus

41 2013. 2-222 p.

42 51. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated
43 Health Economic Evaluation Reporting Standards (CHEERS) statement. *BMJ : British Medical Journal*.
44 2013;346:f1049.

45 52. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed?
46 *Bmj*. 2000;320(7243):1197-200.

47 53. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-
48 parametric bootstrap. *Stat Med*. 2000;19(23):3219-36.

49 54. Remien RH, Patel V, Chibanda D, Abas MA. Integrating mental health into HIV prevention and
50 care: a call to action. *Journal of the International AIDS Society*. 2021;24(S2):e25748.

- 1
2
3 55. UNAIDS. End Inequalities. End AIDS. Global AIDS strategy 2021-2026. Geneva: UNAIDS; 2020.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figure 1: Participant Flow

Figure 2: Stepped Care-AD Flow



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	1
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	1
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1-2
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	2
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	14

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention 4-5

4

5

6 6b Explanation for choice of comparators 5

7

8 Objectives 7 Specific objectives or hypotheses 5

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 5

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained 5

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) 6

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered 8-11, 19

23

24 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) 8-10

25

26 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) 11-13

27

28 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 8-11

29

30 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended 11-12

31

32

33

34 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) 7-8, 20

35

36

37

38

39

40

41

42

43

44

45

46

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	14
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	6, 12-13
5				

6
7 **Methods: Assignment of interventions (for controlled trials)**

8	Allocation:			
9				
10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	7
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	7
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	7
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	13-14
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	13-14
28				
29				
30				

31 **Methods: Data collection, management, and analysis**

32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	11-12
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	12-13
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12-13
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	15-16
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	16
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	16
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	14
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	13-14
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	12, 14
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	13
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	13
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	6
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	12
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	1
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	13-14
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	3, 6
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	17
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	N/A
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
35				
36				

37 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 39 “[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)” license.
 40
 41
 42

BMJ Open

Task-sharing with lay counsellors to deliver a stepped care intervention to improve depression, antiretroviral therapy adherence, and viral suppression in people living with HIV: study protocol for the TENDAI randomised controlled trial.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057844.R2
Article Type:	Protocol
Date Submitted by the Author:	14-Jun-2022
Complete List of Authors:	Abas, Melanie; King's College London, Section of Epidemiology, Health Services & Population Research Mangezi, Walter; University of Zimbabwe, Department of Primary Health Care Sciences, Unit of Mental Health Nyamayaro, Primrose; University of Zimbabwe, Department of Primary Health Care Sciences, Unit of Mental Health Jopling, Rebecca; King's College London, Health Service & Population Research Department Bere, Tarisai; University of Zimbabwe, Department of Primary Health Care Sciences, Unit of Mental Health McKetchnie, Samantha M.; Massachusetts General Hospital, Psychiatry; The Fenway Institute at Fenway Health Goldsmith, Kimberley; King's College London, Department of Biostatistics & Health Informatics Fitch, Calvin; Massachusetts General Hospital, Department of Psychiatry; Fenway Institute Saruchera, Emily; University of Zimbabwe, Department of Primary Health Care Sciences Muronzie, Thabani; University of Zimbabwe, Department of Primary Health Care Sciences Gudyanga, Denford; University of Zimbabwe, Department of Primary Health Care Sciences Barrett, Barbara; King's College London, Health Service & Population Research Department, Institute Of Psychiatry, Psychology & Neuroscience Chibanda, D; University of Zimbabwe, Department of Psychiatry; London School of Hygiene & Tropical Medicine, Centre for Global Mental Health Hakim, James; University of Zimbabwe Medical School Clinical Research Centre Safren, Steven; University of Miami, O'Cleirigh, Conall; Massachusetts General Hospital, Department of Psychiatry; Fenway Institute
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	Mental health

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Depression & mood disorders < PSYCHIATRY, HEALTH ECONOMICS, MENTAL HEALTH, PUBLIC HEALTH

SCHOLARONE™
Manuscripts

Task-sharing with lay counsellors to deliver a stepped care intervention to improve depression, antiretroviral therapy adherence, and viral suppression in people living with HIV: study protocol for the TENDAI randomised controlled trial.

Melanie Abas¹, Walter Mangezi², Primrose Nyamayaro², Rebecca Jopling¹, Tarisai Bere², Samantha M. McKetchnie^{3,4,5}, Kimberley Goldsmith⁶, Calvin Fitch^{3,5,7}, Emily Saruchera², Thabani Muronzie², Denford Gudyanga², Barbara Barrett¹, Dixon Chibanda^{2,8}, James Hakim^{2*}, Steven A. Safren⁹, and Conall O’Cleirigh^{3,5,7}

1. Health Service & Population Research Department, Institute of Psychiatry, Psychology, & Neuroscience, King’s College London, UK
2. Department of Primary Health Care Sciences, Unit of Mental Health, University of Zimbabwe, ZI
3. Behavioral Medicine Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA
4. School of Social Work, Boston College, Newton, Massachusetts, USA
5. The Fenway Institute, Fenway Health, Boston, Massachusetts, USA
6. Department of Biostatistics & Health Informatics, Institute of Psychiatry, Psychology, & Neuroscience, King’s College London, UK
7. Department of Psychiatry, Harvard Medical School, Cambridge, Massachusetts, USA
8. Centre for Global Mental Health, London School of Hygiene and Tropical Medicine, London, UK
9. Center for HIV Research in Mental Health, Department of Psychology, University of Miami, Coral Gables, Florida, USA

Corresponding Author:

Conall O’Cleirigh, Ph.D.
Massachusetts General Hospital
Harvard Medical School
Department of Psychiatry
Boston, MA USA
cocleirigh@mgh.harvard.edu

Trial registration: ClinicalTrials.gov Identifier: NCT04018391

Abstract

Introduction: Non-adherence to antiretroviral therapy (ART) is the main cause of viral non-suppression and its risk is increased by depression. In countries with high burden of HIV there is a lack of trained professionals to deliver depression treatments. This paper describes the protocol for a 2-arm parallel group superiority 1:1 randomised controlled trial, to test the effectiveness and cost-effectiveness of the TENDAI stepped care task-shifted intervention for depression, ART non-adherence, and HIV viral suppression delivered by lay interventionists.

Methods and Analysis: Two hundred and ninety people living with HIV (PLHIV) aged ≥ 18 years with probable depression (Patient Health Questionnaire ≥ 10) and viral non-suppression (≥ 1000 HIV copies per ml) are being recruited from HIV clinics in towns in Zimbabwe. The intervention group will receive a culturally adapted 6-session psychological treatment (PST-AD) including problem-solving therapy, positive activity scheduling, skills to cope with stress and poor sleep, and content to target barriers to non-adherence to ART. Participants whose score on the PHQ-9 remains ≥ 10 , and/or falls by less than 5-points, step up to a nurse-evaluation for possible antidepressant medication. The control group receives usual care for viral non-suppression, consisting of three sessions of adherence counselling from existing clinic staff, and enhanced usual care for depression in line with the WHO Mental Health Gap intervention guide. The primary outcome is viral suppression (< 1000 HIV copies per ml) at 12 months post-randomisation. Ethics and Dissemination: The study and its tools were approved by MRCZ/A/2390 in Zimbabwe and RESCM-18/19-5580 in the United Kingdom. Study findings will be shared through the community advisory group, conferences, and open access publications.

Strengths and Limitations:

Strengths:

- The first randomised controlled trial in a low-income country to test an intervention to improve adherence to antiretroviral therapy (primary outcome) and depression (as a secondary outcome) in people living with HIV.

- Culturally adapted and culturally appropriate intervention to address barriers to adherence to antiretroviral therapy and to treat depression, based on extensive preliminary work.
- Assessment of the cost-effectiveness of the TENDAI stepped care task-shifted intervention
- Stepped care intervention is delivered through task-shifting to non-specialist staff, allowing for future scale up.

Limitation:

- Limited scope to assess implementation science questions given the individually randomised design.

Introduction

Over 27% of people in sub-Saharan Africa currently receiving antiretroviral therapy (ART) are non-adherent (1), and non-adherence to ART is the main cause of viral non-suppression (2). Achieving and maintain viral suppression is not only an effective HIV treatment strategy but also an effective HIV prevention approach, preventing transmission of the virus to sexual partners, and from mother to child (3, 4). Depression is among the strongest correlates of non-adherence and affects over 15% of PLHIV attending HIV outpatient clinics in sub-Saharan Africa (1, 5, 6). Depression is linked to non-adherence through the reduced motivation and forgetting to take ART (7), through impaired problem-solving ability (8), and may interfere with uptake of existing adherence support programs as part of clinical care (9, 10). Depression may also impact adherence through its association with structural factors, such as poverty, and interpersonal difficulties which impede access to HIV medication (7, 10, 11). Non-adherence to ART may also precede and increase risk of depression (12). Evidence-based interventions for depression include psychological interventions based on cognitive behavioural approaches, and antidepressant medication (13)

Countries with high burden of HIV, such as Zimbabwe, have a dearth of trained mental health professionals. Given the public health importance of viral suppression (14), and the strong association with depression, adherence interventions must address comorbid psychological factors and be able to be delivered through task-shifting to non-specialists (15). Systematic reviews of mental health interventions in PLHIV in low resource settings have

1
2
3 been unable to report effects on HIV outcomes as, to date, these have not been studied (16,
4
5 17).

6
7
8 The most promising evidence for the effectiveness and utility of integrated treatments
9
10 for depression and ART adherence for PLHIV has come from the development of Cognitive
11
12 Behavioural Therapy for Adherence and Depression (CBT-AD) in the United States (18, 19).
13
14 CBT-AD, which includes the “Life Steps” intervention for addressing barriers to medication
15
16 adherence, has been shown to improve rates of ART adherence, and to reduce depression
17
18 severity among men in the US (20 , 21). In contrast, interventions for PLWH with depression
19
20 and poor adherence which *only* target mood have not been found to improve viral suppression
21
22 (22). Recent reports, including from our team in Zimbabwe, support the acceptability and
23
24 feasibility of culturally-adapted cognitive behavioural interventions for low resource settings
25
26 (23-25). However, there have yet to be any definitive RCTs from low resource settings
27
28 focused on treatment of depression and ART adherence to improve viral suppression (26).
29
30 Thirteen percent of the adult population in Zimbabwe is living with HIV, with 22% of those
31
32 virally non-suppressed (22). The objective of this trial is to test the effectiveness and cost-
33
34 effectiveness of the TENDAI stepped care psychological intervention for adherence to ART
35
36 and depression, (Stepped Care-AD), compared to enhanced usual care, for PLHIV in
37
38 Zimbabwe with viral non-suppression and depression. TENDAI is derived from principles of
39
40 problem-solving and psychoeducation for depression and adherence, and motivational
41
42 interviewing.

43 44 45 46 47 48 49 **Methods and Analysis**

50 51 **Study Design and Setting**

52
53 The study is a two-arm parallel group superiority 1:1 randomised effectiveness trial
54
55 (n=290). PLHIV receive care according to the standard national guidelines (27). Viral load is
56
57 monitored every 12 months, with more frequent screening every 3 months for those who are
58
59
60

1
2
3 virally non-suppressed. Participants are being recruited from two sites in Zimbabwe
4 providing HIV services for those initiated on ART. These are the Marondera Provincial
5 Hospital, and Chitungwiza Central Hospital, along with satellite clinics for each hospital.
6
7 Marondera is the capital of Mashonaland East province, situated in the north east of
8 Zimbabwe. The town and its surrounding district have a total population of approximately
9
10 224,000 (28). Chitungwiza is an urban town, divided into five townships, with a total
11
12 population of approximately 391,000 (29). Taken together, both sites combined have
13
14 approximately 25,000 adults registered as receiving ART.
15
16
17
18
19
20
21

22 **Patient and Public Involvement**

23
24 No patient involvement in the design of the study. Results will be disseminated to
25 study participants and community members via local advisory groups.
26
27

28 **Eligibility Criteria**

29
30 Inclusion criteria: 1) HIV positive and initiated on ART for at least 6 months; 2)
31 clinically significant depression symptoms (operationalised as a score of 10 or more on the
32 locally validated Patient Health Questionnaire (PHQ-9) which has been validated for adults in
33 a primary care population with high HIV prevalence in Zimbabwe (6)); 3) virally non-
34 suppressed in the past 2 months (viral load \geq 1000 copies/mL); 4) able to provide informed
35 consent ; and 5) if prescribed anti-depressants, have been on a stable anti-depressant regimen
36 for at least 2 months. Exclusion criteria: 1) unwilling or unable to provide informed consent;
37
38 2) major untreated or undertreated mental illness (e.g. untreated psychosis or mania, actively
39 suicidal assessed using the MINI and P4 suicide screener), major or advanced physical
40 disease (assessed using clinic records) or severe cognitive impairment (assessed using the
41 International HIV dementia scale) which would interfere with engagement in Stepped Care-
42 AD; 3) have received a course of problem solving therapy or cognitive-behavioural
43 psychological therapy for depression; or 4) <18 years old.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study Procedures

Recruitment and Informed Consent

See Figure 1 for study flow. Research Assistants (RAs) in the ART clinic approach patients identified by clinic staff as having a detectable viral load (>1000 copies/mL) in the past 2 months or at high risk of viral non-suppression, e.g., self-reported poor adherence. Potentially eligible individuals will complete a brief screen for inclusion and exclusion criteria. Those meeting initial screening eligibility criteria are invited to complete informed consent procedures and the full baseline assessment. Informed consent will include consent to access participants' medical records, and for telephone calls and home visits if needed for follow-up. Capacity to provide consent is assessed by a licensed psychiatrist (WM) for any participant indicating consent but suspected of being unable to fully understand and/or retain information provided.

Baseline

A trained RA collects data by face-to-face interview including: demographics, measures of socio-economic position (employment status, educational history, and ownership of household assets) (30, 31), depression using the Patient Health Questionnaire (PHQ-9) (6), anxiety using the Hospital Anxiety and Depression Scale (32) quality of life using The EQ-5D-3L (33), use of alcohol and substances (34, 35), cognitive impairment using the International HIV Dementia Scale (36), psychiatric diagnosis using the MINI International Neuropsychiatric Interview (37), use of health services in the last 4 months using a modified version of the Client Services Receipt Inventory (31) and several additional exploratory measures. Current ART regimen and recent CD4 test results are taken directly from participants medical records.

Viral load in the past 60 days is ascertained from the participants medical records, or, for those who have not been tested in the past two months, by testing plasma.

Eligibility

The study team, including a clinical psychologist or psychiatrist, will meet weekly via teleconference to discuss each baseline assessment and confirm that participants meet eligibility criteria.

Randomisation

Approximately 2 weeks after the baseline assessment, eligible participants return for a randomisation visit and are randomly assigned to Stepped Care-AD or enhanced usual care (EUC). Randomisation is determined by a computer-generated chart and is conducted via the REDCap randomisation module by the Zimbabwe site Programme Manager.

Follow-Up Assessments

In addition to baseline, there are 3 major study assessments: 4-, 8-, and 12-months post-randomisation. An Independent Assessor (IA) who is blind to study condition will administer the PHQ-9, EQ-5D-3L, and self-report medication adherence measures only. RAs will collect all other self-report data including use of alcohol and substances (34, 35), Hospital Anxiety and Depression Scale for Anxiety (32), quality of life (33), and use of other health care services (38). At the final 12-month follow-up, we will also extract chart information from medical records for pharmacy refill data and HIV viral load results. Participants without a viral load test in the past 30 days are invited to undergo venepuncture for viral load testing, which is in addition to the venepuncture for ART detection.

Interventions

Active Intervention Arm: Task-sharing Stepped Care Intervention for Adherence and Depression (TENDAI Stepped Care-AD).

As shown in Figure 2, all participants in the TENDAI arm receive six 50-minute sessions of a culturally adapted intervention for depression and non-adherence to ART delivered weekly, followed by one booster session six weeks later. The intervention is based

1
2
3 on cognitive behavioural principles and includes problem-solving therapy, positive activity
4 scheduling, skills to cope with stress and poor sleep, and content to target barriers to non-
5 adherence to ART. Training of interventionists emphasises common elements of effective
6 psychological interventions including empathy, active listening, and creating realistic hope
7
8 (39). The training is conducted by the principal investigators and other clinical psychologists
9 with expertise in the intervention. Refresher trainings and ongoing supervision will be
10 conducted throughout the study.
11
12
13
14
15
16
17
18

19 A) Adherence to antiretroviral therapy. Session 1 comprises a locally adapted version
20 of the Lifesteps adherence intervention called *Nzira Itsva* (18, 40). This includes motivation,
21 goal setting, video-based education and problem solving. Motivational interviewing is used to
22 identify the participants' life goals and to tie adherence to achieving these goals. Education
23 about on time adherence is provided using an animated video in the Shona language. Barriers
24 to adherence are assessed through a culturally adapted checklist. During each of the
25 subsequent sessions 2-6 targeting depression, 5- to 10-minute adherence boosters are
26 included to review adherence to ART and the participants' experience with strategies to
27 overcome barriers to adherence.
28
29
30
31
32
33
34
35
36
37
38
39

40 B) Psychological intervention for depression. Sessions 2 and 3 focus on
41 psychoeducation about depression and problem-solving therapy (PST) (41), incorporating
42 storytelling and illustrations, and training in problem-solving. A goal for each session is to
43 identify a defined specific problem to work on, to collaboratively agree a solution to work on
44 and to schedule homework. An intervention based on PST has been shown to be acceptable
45 and effective for depression in Zimbabwe (42, 43). In Session 4 participants are encouraged
46 to choose and schedule at least four adaptive activities in which to engage: an activity that
47 promotes a sense of achievement, a physical activity, a pleasurable activity, and a social
48 activity. Homework is mutually agreed as part of every session, to test out participants'
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 implementation of solutions to problems, and of positive activities. Thorough review of
4 homework is done at each session, including barriers to doing homework. Skills to promote
5 good sleep and relaxation are taught in Sessions 5 and 6. A relapse prevention plan is
6 developed in session 6 including triggers for relapse of depression, warning signs, coping
7 strategies and self-care activities. Fidelity of the intervention will be assessed through rating
8 10% of audio-recorded sessions for adherence to the intervention protocol and for therapist
9 competence (44).

10
11
12
13
14
15
16
17
18
19 C) Booster session. About six weeks after the sixth session, participants are invited to
20 a 50-minute booster session. This includes a review of depressive symptoms, and of
21 adherence to HIV treatment and, where appropriate, adherence to antidepressant medication.
22 The session includes ongoing positive activity scheduling to promote recovery from
23 depressive symptoms.

24
25
26
27
28
29
30
31 D) Stepped up care. Participants with persistent depression (depression score
32 continuing above cut-off (PHQ-9 ≥ 10) or if they have less than a 5-point improvement in
33 PHQ-9 score) after at least 4 sessions receive step up to a nurse-evaluation for antidepressant
34 medication. The antidepressant Fluoxetine is offered for those with confirmed depression.

35 36 37 38 39 40 **Control Arm: Enhanced Usual Care (EUC)**

41
42 All participants in the control arm receive Enhanced Usual Care (EUC) comprising
43 usual care for viral non-suppression, and enhanced usual care for depression in line with the
44 WHO Mental Health Gap intervention guide. Usual care for those with viral non-suppression
45 includes three sessions of adherence counselling provided by an adherence counsellor, nurse,
46 or NGO support worker based at the clinic. These sessions include establishing the
47 participants knowledge about HIV and ART, providing information about use of ART,
48 encouraging adherence, and describing barriers to adherence. Strategies commonly used
49 include encouraging use of an alarm and a treatment supporter, linking ART taking to daily
50
51
52
53
54
55
56
57
58
59
60

1
2
3 routines, and disclosure of HIV status. The first session is given on the day of receiving viral
4 load results, with two subsequent sessions scheduled on a monthly basis. Referrals may be
5 made to local support groups or organisations for social or economic support, general
6 psychological support or to an HIV clinician. The HIV operational strategy recommends that
7 all patients living with HIV and registered at facility should be screened for common mental
8 disorders (CMD) annually. Patients with high viral load or those initiating ART should be
9 screened for CMD at their appointment (45). Patients exhibiting symptoms of common
10 mental disorders or psychological distress should be managed with counselling interventions
11 and are usually referred to the outpatient's department to be assessed by a Psychiatric nurse.
12 If they require further treatment, they will be seen by a psychiatrist. Patients can also be
13 referred to community-based organization to receive psychosocial services (45). Usual care
14 for depression is enhanced in three ways: 1) The study team will train all health service
15 providers in the study sites on psychological and antidepressant management of depression
16 using the WHO Mental Health Gap intervention guide (mhGAP) (46); 2) we will provide a
17 letter for each participant communicating the patients PHQ-9 score and probable depression
18 to their HIV-care provider; and 3) we will provide those in the EUC condition with access to
19 Stepped Care-AD upon completion of their 12-month follow-up visit.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Outcomes**

42 **Primary Outcome**

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Viral suppression at 12-months post-randomisation follow-up (defined as <1000 copies/mL), measured through blood (plasma). This measure will be taken from the medical record if viral load was collected within 30 days of the expected visit date or through study specific assay if not in the medical record.

Secondary Outcomes

- 1
2
3 1. Depression at 12 months post-randomisation measured as the total score on the
4 Patient Health Questionnaire (PHQ-9) (6).
5
6
- 7
8 2. Adherence to ART medication at 4-, 8-, and 12-months post randomisation assessed
9 as the proportion of the sample achieving at least 90% adherence in the past month
10 assessed through pharmacy refill (47).
11
12
- 13
14 3. Self-reported adherence to ART medication at 4-, 8-, and 12-months post
15 randomisation assessed as the frequency of adherence in the past 30 days measured
16 using a score derived from a three-item questionnaire adapted from Wilson et al.
17 (2015)(48).
18
19
- 20
21 4. Viral load copies/mL at 12-months post-randomisation follow-up measured as mean
22 log Viral Load.
23
24
25
26
27

28 **Tertiary Outcomes**

29
30 The total costs of the health care services used by each study participant will be
31 calculated using service use information collected from hospital records and from participant
32 self-report (via a modified version of the Client Services Receipt Inventory suitable for use in
33 sub-Saharan Africa (38)) at 4-, 8-, and 12-month follow-up and with unit costs identified and
34 calculated using locally available data. Detailed information on the use of Stepped Care-AD
35 and EUC will be collected from therapist records. Quality of life at 4, 8 and 12 months is
36 measured using EQ-5D-3L (33). Quality-adjusted life years will be calculated using
37 Zimbabwe-specific health states (49).
38
39
40
41
42
43
44
45
46
47
48

49 **Data Collection and Management**

50
51 Trial data is collected and stored in REDCap, a data management tool designed for
52 collection and protection of patient health information. The REDCap database is hosted and
53 routinely audited at Massachusetts General Hospital (MGH), with access restricted via user
54 roles. Data extracts are sent to the study statisticians, via secure file transfer. To ensure
55
56
57
58
59
60

1
2
3 accuracy of collected data, MGH staff generate weekly error reports. These error reports are
4
5 then sent to staff in Zimbabwe, who correct any discrepancies and document changes made to
6
7 the database.
8
9

10 **Strategies to Improve Participant Retention**

11
12 Procedures to maximise participant retention include sending text message reminders
13
14 before scheduled appointments and collection of locator information (e.g., contact
15
16 information of two significant others with whom the participant is in regular contact).
17
18 Participants are also provided with refreshments at study visits and reimbursed transport
19
20 costs. Although those in the EUC arm have fewer scheduled clinical sessions, the same total
21
22 amount (\$46) will be provided to participants attending all clinical sessions and research
23
24 assessments in both arms. We will make efforts to retain individuals who move to a non-
25
26 study site for their HIV care and are willing to complete follow-up. Where participants are
27
28 unable to travel to the clinic to complete follow up assessments (e.g. because of COVID-19
29
30 lockdown travel restriction), participants will be offered phone assessments. Where
31
32 participants can not be reached by phone, a home visit may be conducted.
33
34
35
36

37 **Confidentiality**

38
39
40 Participants are given a study-specific identification number at screening that is used
41
42 on all forms and data collection instruments, excluding the consent form. Participants are
43
44 referred to only by their identification number during eligibility and supervision meetings. A
45
46 file that links participant names to identification numbers is stored in a locked file at the
47
48 University of Zimbabwe.
49
50

51 **Blinding**

52
53
54 To reduce bias and maximise the validity of the findings, the Independent Assessor
55
56 (IA) for the primary and secondary outcomes, and the lead study statistician, are blinded to
57
58 randomisation condition. To ensure blinding, the IA will explain their role to participants and
59
60

ask that they do not give the IA information about the treatment they received. The lead study statistician will not attend meetings where randomisation or clinical issues are discussed, and their access in REDCap is restricted so that they cannot view any data or report that may unblind them. A second statistician, who will conduct the analyses and will review data for thoroughness and completeness, will not be blinded. This trial does not have procedures for unblinding IAs or the lead study statistician. If the IA is concerned about the safety of a participant, they will communicate the concern to study staff, who will contact the clinical supervisor.

Data Safety and Monitoring Board (DSMB)

A DSMB, consisting of members with experience in clinical trials for mental disorders, biostatistics, HIV in African settings, and human subject protection issues will function independent of the sponsor and monitor safety of study participants and integrity of data. The DSMB will meet annually and receive safety information in an unblinded manner. Expedited review by the DSMB will occur for all serious adverse events (SAE) as defined as any fatal, immediately life-threatening, or substantially disabling event; event requiring or prolonging inpatient hospitalisation, or any congenital anomaly.

Statistical Methods

Sample Size

Using two-sided Fisher's exact test, $\alpha = 0.05$ and 20% attrition, a sample size of 290 participants will provide 85% power to detect an absolute difference of 20% or more in achieving viral suppression (e.g. 45% in the EUC arm vs. 65% in the intervention arm) at 12-months follow-up. Pilot data showed a larger difference between arms (50% in the EUC arm vs. 75% in the intervention arm) (24), suggesting this should be a conservative sample size estimate.

Statistical Methods for Primary and Secondary Outcomes

1
2
3 Baseline and outcome variables will be summarised using appropriate statistics; no
4
5 baseline statistical comparisons will be made. The main analysis will follow intention to treat
6
7 principles, reporting appropriate 95% confidence intervals and use a 5% significance level.
8
9

10 All models will include a site stratification variable. In the mixed models we will have
11
12 random intercepts at the participant level, and random slopes if warranted (assessed via
13
14 likelihood ratio test).
15

16
17 Twelve-month primary outcome viral load will be coded as suppressed (<1000
18
19 copies/mL) vs not suppressed (\geq 1000 copies/mL). If these data are missing and we have no
20
21 further information, they will be left as missing. If we do have information from medical or
22
23 death records that the individual died from high viral load or AIDS related reasons, we will
24
25 code them as not being virally suppressed. . Suppressed/not suppressed will be the dependent
26
27 variable in a logistic regression model estimating the TENDAI vs EUC odds ratio (OR), with
28
29 trial arm as the independent variable. The mean difference in PHQ-9 depression and self-
30
31 report adherence will each be estimated using a linear mixed effects model with the 4-, 8- and
32
33 12-month measures as dependent variables, with the baseline measure of the outcome, time,
34
35 and trial arm by time interaction terms as independent variables. The OR at 4, 8 and 12
36
37 months for \geq 90% adherence vs <90% adherence by pharmacy refill in the past 30 days will
38
39 be estimated using a logistic mixed effects model with the 4, 8 and 12-month measures as
40
41 dependent variables, and independent variables as described for PHQ-9 and self-report
42
43 adherence. The mean difference in log copies/mL of viral load at 12 months will be estimated
44
45 using a linear regression model with log viral load at 12 months as the dependent variable,
46
47 trial arm and baseline log viral load as independent variables. In line with other recent and
48
49 similar trials in HIV and methodology literature (50-56), we do not plan to undertake
50
51 secondary outcome adjustment for multiple comparisons. Rather we will focus on our single
52
53 pre-specified primary outcome to assess effectiveness and take a “precise
54
55
56
57
58
59
60

1
2
3 interpretation"/separate hypotheses approach for the secondary outcomes in combination with
4 appropriate reporting of effect sizes and confidence intervals to support transparent
5
6 interpretation (52, 56).
7
8
9

10 A "per protocol" analysis for the primary viral load outcome only will exclude
11 participants not completing at least four TENDAI sessions, and anyone found to be ineligible
12 post randomisation. No interim or formal powered subgroup analyses are planned, however,
13
14 we will explore moderation by gender for viral suppression, self-report adherence and
15 depression outcomes by adding a sex by trial arm (by time, where appropriate) interaction
16
17 term to the final outcome analysis models. Additional exploratory mediation analysis (e.g., to
18
19 examine changes in both depression and adherence as mediators of treatment related changes
20 in viral load) is planned, but will not be reported on in the main paper. This analysis should
21
22 help elucidate whether intervention effects were due to improving depression or more directly
23 by changing adherence. Missing baseline measures will be imputed using simple mean
24
25 imputation (57). Missing repeatedly measured outcome data will be handled using mixed
26
27 models/maximum likelihood methods, including baseline variables predicting missing
28
29 outcome data. If there is more than 10% missing primary outcome data and post-
30
31 randomisation variables (completion of therapy in the TENDAI arm only and ART adherence
32
33 at 12 months) predict whether these data are missing, we will consider multiple imputation
34
35 (MI) (58).
36
37
38
39
40
41
42
43
44
45
46

47 Cost-effectiveness results will be reported following CHEERS guidelines (59).
48
49 Economic evaluations can be used to inform healthcare decision makers on the total budget
50
51 needed to treat people with a particular disease or condition; it is only the mean cost that
52
53 allows for this calculation to be made. Thus, it is the arithmetic mean cost that is the relevant
54
55 summary statistic in pragmatic trials with economic evaluations and the mean average total
56
57 cost in each randomised group will be calculated and compared between the two groups using
58
59
60

1
2
3 standard t-tests, despite the likely skewed nature of the data (60). As is common in the
4
5 analysis of cost data, the robustness of the mean cost comparisons will be confirmed through
6
7 the calculation of nonparametric bootstrapped confidence intervals (61). The primary cost-
8
9 effectiveness will consider costs together with the dichotomous primary outcome measure
10
11 (viral suppression <1000 copies/mL), generating information on the incremental cost per
12
13 successful case (in the form of an incremental cost-effectiveness ratio) and the probability
14
15 that the TENDAI is cost-effective compared to enhanced usual care given available
16
17 information. A secondary cost-utility analysis will also be completed, which will report the
18
19 cost per QALY of the TENDAI intervention compared to enhanced usual care via
20
21 incremental cost-effectiveness ratios. Analyses will be adjusted for costs and outcomes.
22
23 Sensitivity analyses will be carried out to test the robustness of costing assumptions to
24
25 variation.
26
27
28
29

30 **Discussion**

31
32
33
34 In Zimbabwe, both HIV and co-morbid depression are common, yet, as in other low-
35
36 resource settings with high HIV burden, there is a lack of evidence on interventions to
37
38 improve both ART adherence and depression (62). Due to resource limitations, interventions
39
40 that allow for task-shifting and administration by community health workers are particularly
41
42 well-placed to be effective and sustainable. Our treatment, Stepped Care-AD, blends active
43
44 ingredients of treatment for depression with a culturally-adapted LifeSteps intervention to
45
46 enhance adherence to ART (24, 40). If successful, the Stepped Care-AD intervention
47
48 represents a useful model for policy and for further research. As the primary outcome of the
49
50 trial is viral suppression, its implementation in Zimbabwe and other low-resource settings
51
52 may further the UNAIDS goal of ending the AIDS epidemic by 2030, through optimising
53
54 viral suppression (63). Results gathered in a Zimbabwean context may be leveraged for
55
56
57
58
59
60

1
2
3 testing and implementation of similar task-shifted stepped care interventions in other Sub-
4
5 Saharan African settings.
6
7

8 9 **Ethics and Dissemination**

10
11 All study procedures were reviewed and approved by ethics committees at King's
12
13 College London (RESCM-17/18-5580), Massachusetts General Hospital (IRB00012706), and
14
15 the Medical Research Council of Zimbabwe (MRCZ/A/2390). Serious adverse events (SAEs)
16
17 will be reported to research ethics committees at King's College London, MGH, and the
18
19 Medical Research Council of Zimbabwe within 72 hours.
20
21

22
23 Dissemination of findings will involve three primary papers describing the study
24
25 outcomes, as well as submitting to lead workshops on the treatment approach at relevant
26
27 national meetings and conferences. Additionally, data will be available to external parties
28
29 after publication of the outcome papers via PI-approved application. Data will be stored
30
31 indefinitely.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Trial Status

This trial began recruitment and enrolment on 2nd July 2019.

Acknowledgements

Mercy Mundwa, Oline Chivere, Sheila Marezva, Vimbai Gwata, Rumbidzai Nyanda, Moreblessing Phiri, Megan R. Wirtz, Rachel Holland, Dr Tsitsi Apollo, Dr Celestino Dhege, Dr Michael Chiwanga, Tinashe Macheka, and Isaac Masarira,

KG contributions to this paper represent independent research part funded by the NIHR Biomedical Research Centre (South London and Maudsley NHS Foundation Trust and KCL) and the NIHR Applied Research Collaboration South London (King's College Hospital NHS Foundation Trust). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

This work is funded by National Institute of Mental Health. Grant number: 1R01MH114708

Figure Legend

Figure 1. Flow of Participants through TENDAI Study.
Figure 2. Stepped Care-AD Intervention Flow Diagram.

Funding: R01 MH114708 awarded to Prof Abas and Dr O'Cleirigh by the National Institute of Mental Health (NIMH), NIH.

Date and Version: 10 June 2022, version 3.0

Competing Interests: The authors do not have any conflicts of interest to report.

Data Sharing: Trial data will be shared upon reasonable request.

Roles of Contributors

Melanie A Abas: Professor Abas is the King's College London PI for the trial and engaged in substantial writing of this manuscript and gaining funding for the study.

Walter Mangezi: Dr. Mangezi is the University of Zimbabwe PI for the trial and engaged in revision of this manuscript and gaining funding for the study.

Primrose Nyamayaro: Ms. Nyamayaro is the University of Zimbabwe Project Director for the trial and engaged in revision of this manuscript.

Rebecca Jopling: Ms. Jopling is the King's College London Project Director for the trial and engaged in substantial writing of this manuscript.

Tarisai Bere: Mrs. Bere is the University of Zimbabwe Clinical Supervisor for the trial and engaged in substantial writing of this manuscript.

Samantha M. McKetchnie: Mrs. McKetchnie is the trial Data Manager and engaged in substantial writing of this manuscript.

Kimberley Goldsmith: Dr. Goldsmith is the Trial Statistician and engaged in substantial writing of this manuscript and gaining funding for the study.

Calvin Fitch: Dr. Fitch is the Massachusetts General Hospital Clinical Supervisor for the trial and engaged in revision of this manuscript.

Emily Saruchera: Mrs. Saruchera is the Senior Research Assistant for this trial and engaged in substantial writing of this manuscript.

Thabani Muronzie: Mr. Muronzie is a Research Assistant for this trial and engaged in substantial writing of this manuscript.

Denford Gudyanga: Mr. Gudyanga is a Research Assistant for this trial and engaged in substantial writing of this manuscript.

Barbara Barrett: Dr. Barrett is the Trial Health Economist and engaged in revision of this manuscript. and gaining funding for the study

Dixon Chibanda: Dr. Chibanda is a Co-Investigator on this trial and provided guidance around the development and execution of this manuscript and gaining funding for the study.

James Hakim: Professor. Hakim was a Co-Investigator on this trial. He assisted in gaining funding for the study and provided guidance around the development and execution of this manuscript up until his untimely death in 2020.

Steven A. Safren: Professor. Safren is a Co-Investigator on this trial and provided guidance around the development and execution of this manuscript and gaining funding for the study.

Conall O'Cleirigh: Dr. O'Cleirigh is the Massachusetts General Hospital PI for the trial and engaged in substantial writing of this manuscript and assisted in gaining funding for the study.

Sponsor: The National Institute of Mental Health provides funding for this trial and monitors progress on the project through yearly Research Performance Progress Reports.

References

1. Heestermans T, Browne JL, Aitken SC, Vervoort SC, Klipstein-Grobusch K. Determinants of adherence to antiretroviral therapy among HIV-positive adults in sub-Saharan Africa: a systematic review. *BMJ Glob Health*. 2016;1(4):e000125.
2. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. *J Infect Dis*. 2008;197 Suppl 3:S272-8.
3. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011;365(6):493-505.
4. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. *J Acquir Immune Defic Syndr*. 2002;29(5):484-94.
5. Lofgren SM, Bond DJ, Nakasujja N, Boulware DR. Burden of Depression in Outpatient HIV-Infected adults in Sub-Saharan Africa; Systematic Review and Meta-analysis. *AIDS and behavior*. 2020;24(6):1752-64.
6. Chibanda D, Verhey R, Gibson LJ, Munetsi E, Machando D, Rusakaniko S, et al. Validation of screening tools for depression and anxiety disorders in a primary care population with high HIV prevalence in Zimbabwe. *Journal of affective disorders*. 2016;198:50-5.
7. Wagner GJ, Slaughter M, Ghosh-Dastidar B. Depression at Treatment Initiation Predicts HIV Antiretroviral Adherence in Uganda. *Journal of the International Association of Providers of AIDS Care*. 2017;16(1):91-7.
8. Safren SA, Radomsky AS, Otto MW, Salomon E. Predictors of psychological well-being in a diverse sample of HIV-positive patients receiving highly active antiretroviral therapy. *Psychosomatics*. 2002;43(6):478-85.
9. Andersen L, Kagee A, O'Cleirigh C, Safren S, Joska J. Understanding the experience and manifestation of depression in people living with HIV/AIDS in South Africa. *AIDS Care*. 2015;27(1):59-62.
10. Kidia K, Machando D, Bere T, Macpherson K, Nyamayaro P, Potter L, et al. 'I was thinking too much': experiences of HIV-positive adults with common mental disorders and poor adherence to antiretroviral therapy in Zimbabwe. *Trop Med Int Health*. 2015;20(7):903-13.
11. Kalichman SC, Kalichman MO, Cherry C. Forget about forgetting: structural barriers and severe non-adherence to antiretroviral therapy. *AIDS care*. 2017;29(4):418-22.
12. Wing RR, Phelan S, Tate D. The role of adherence in mediating the relationship between depression and health outcomes. *J Psychosom Res*. 2002;53(4):877-81.
13. Abas MA. Combining active ingredients to treat depression in the wake of COVID-19. *The Lancet Psychiatry*. 2022;9(3):190-1.
14. UNAIDS. Prevailing against pandemics by putting people at the centre. Geneva; 2020.
15. Abas M, O'Cleirigh C. Global mental health and the ambition to end AIDS by 2030. *The Lancet Psychiatry*. 2018;5(11):867-9.
16. Nakimuli-Mpungu E, Musisi S, Smith CM, Von Isenburg M, Akimana B, Shakarishvili A, et al. Mental health interventions for persons living with HIV in low- and middle-income countries: a systematic review. *Journal of the International AIDS Society*. 2021;24(S2):e25722.
17. Sikkema KJ, Dennis AC, Watt MH, Choi KW, Yemeke TT, Joska JA. Improving mental health among people living with HIV: a review of intervention trials in low- and middle-income countries. *Glob Ment Health (Camb)*. 2015;2:e19.
18. Safren SA, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, et al. Two strategies to increase adherence to HIV antiretroviral medication: Life-Steps and medication monitoring. *Behaviour Research and Therapy*. 2001;39(10):1151-62.
19. Safren SA, Hendriksen ES, Mayer KH, Mimiaga MJ, Pickard R, Otto MW. Cognitive-Behavioral Therapy for HIV Medication Adherence and Depression. *Cognitive and Behavioral Practice*. 2004;11(4):415-24.

20. Safren SA, O'Cleirigh C, Skeer MR, Driskell J, Goshe BM, Covahey C, et al. Demonstration and evaluation of a peer-delivered, individually-tailored, HIV prevention intervention for HIV-infected MSM in their primary care setting. *AIDS Behav.* 2011;15(5):949-58.
21. Safren SA, Bedoya CA, O'Cleirigh C, Biello KB, Pinkston MM, Stein MD, et al. Cognitive behavioural therapy for adherence and depression in patients with HIV: a three-arm randomised controlled trial. *The Lancet HIV.* 2016;3(11):e529-e38.
22. Pence BW, Gaynes BN, Adams JL, Thielman NM, Heine AD, Mugavero MJ, et al. The effect of antidepressant treatment on HIV and depression outcomes: the SLAM DUNC randomized trial. *Aids.* 2015;29(15):1975-86.
23. Andersen LS, Magidson JF, O'Cleirigh C, Remmert JE, Kagee A, Leaver M, et al. A pilot study of a nurse-delivered cognitive behavioral therapy intervention (Ziphamandla) for adherence and depression in HIV in South Africa. *J Health Psychol.* 2018;23(6):776-87.
24. Abas M, Nyamayaro P, Bere T, Saruchera E, Mothobi N, Simms V, et al. Feasibility and Acceptability of a Task-Shifted Intervention to Enhance Adherence to HIV Medication and Improve Depression in People Living with HIV in Zimbabwe, a Low Income Country in Sub-Saharan Africa. *AIDS Behav.* 2018;22(1):86-101.
25. Nyamayaro P, Bere, T, Magidson, J, Simms, V, O'Cleirigh, C, Chibanda, D, & Abas, MA A task-shifted intervention for depression integrated with counselling for antiretroviral therapy adherence for people living with HIV/AIDS in Zimbabwe. *Global Mental health.* 2016; Under review.
26. Jopling R, Nyamayaro P, Andersen LS, Kagee A, Haberer JE, Abas MA. A Cascade of Interventions to Promote Adherence to Antiretroviral Therapy in African Countries. *Current HIV/AIDS Reports.* 2020;17(5):529-46.
27. National Medicines and Therapeutics Policy Advisory Committee (NMTPAC) and The AIDS and TB Directorate Ministry of Health and Child Care Zimbabwe. *Guidelines for Antiretroviral Therapy for the Prevention and Treatment of HIV in Zimbabwe.* Harare Zimbabwe; 2016.
28. Zimbabwe National Statistics Agency. *Mashonaland East Province District Population Projections Report.* Harare; 2020.
29. PopulationStat. *Chitungwiza Zimbabwe Population 2021* [Available from: <https://populationstat.com/zimbabwe/chitungwiza>].
30. Falkingham J, Namazie C, . *Measuring health and poverty: a review of approaches to identifying the poor:* Department for International Development Health Systems Resource Centre; 2002.
31. Wambogo EA, Ghattas H, Leonard KL, Sahyoun NR. Validity of the Food Insecurity Experience Scale for Use in Sub-Saharan Africa and Characteristics of Food-Insecure Individuals. *Current Developments in Nutrition.* 2018;2(9).
32. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand.* 1983;67(6):361-70.
33. Jelsma J, Hansen K, De Weerd W, De Cock P, Kind P. How do Zimbabweans value health states? *Population Health Metrics.* 2003;1(1):1.
34. Babor TF, De La Fuente MF, Saunders JB, Grant M. *AUDIT - The Alcohol use Disorders Identification Test: Guidelines for use in Primary Health Care.* Geneva, Switzerland: World Health Organization; 1989.
35. Hildebrand M. The Psychometric Properties of the Drug Use Disorders Identification Test (DUDIT): A Review of Recent Research. *J Subst Abuse Treat.* 2015;53:52-9.
36. Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. *Aids.* 2005;19(13):1367-74.
37. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *Journal of Clinical Psychiatry.* 1998;59 Suppl 20:22-33;quiz 4-57.

- 1
2
3 38. Mogga S, Prince M, Alem A, Kebede D, Stewart R, Glozier N, et al. Outcome of major
4 depression in Ethiopia: Population-based study. *British Journal of Psychiatry*. 2006;189(3):241-6.
5 39. Wampold BE. How important are the common factors in psychotherapy? An update. *World*
6 *psychiatry : official journal of the World Psychiatric Association (WPA)*. 2015;14(3):270-7.
7 40. Bere T, Nyamayaro P, Magidson JF, Chibanda D, Chingono A, Munjoma R, et al. Cultural
8 adaptation of a cognitive-behavioural intervention to improve adherence to antiretroviral therapy
9 among people living with HIV/AIDS in Zimbabwe: Nzira Itsva. *Journal of Health Psychology*.
10 2017;22(10):1265-76.
11 41. D'Zurilla T, Nezu A. Problem-Solving Therapy. In: Keith S. Dobson, editor. *Handbook of*
12 *Cognitive-Behavioral Therapies, Third Edition*. United States of America: The Guilford Press; 2010.
13 42. Abas M, Bowers T, Manda E, Cooper S, Machando D, Verhey R, et al. 'Opening up the mind':
14 problem-solving therapy delivered by female lay health workers to improve access to evidence-
15 based care for depression and other common mental disorders through the Friendship Bench
16 Project in Zimbabwe. *International Journal of Mental Health Systems*. 2016;10(1):1-8.
17 43. Chibanda D, Weiss HA, Verhey R, et al. Effect of a primary care-based psychological
18 intervention on symptoms of common mental disorders in zimbabwe: A randomized clinical trial.
19 *JAMA*. 2016;316(24):2618-26.
20 44. Kohrt BA, Jordans MJD, Rai S, Shrestha P, Luitel NP, Ramaiya MK, et al. Therapist
21 competence in global mental health: Development of the ENhancing Assessment of Common
22 Therapeutic factors (ENACT) rating scale. *Behaviour Research and Therapy*. 2015;69:11-21.
23 45. AIDS & TB Programme Ministry of Health and Child Care Zimbabwe. *Operational and Service*
24 *Delivery Manual for the Prevention, Care and Treatment of HIV in Zimbabwe*. Zimbabwe: Ministry of
25 Health and Child Care,; 2017.
26 46. WHO. mhGAP Mental Health Gap Action Programme: Scaling up care for mental,
27 neurological and substance use disorders. Geneva: World Health Organisation; 2010.
28 47. Nau D. Proportion of days covered (PDC) as a preferred method of measuring medication
29 adherence. *Pharm Qual Alliance*. 2012.
30 48. Wilson IB, Lee Y, Michaud J, Fowler FJ, Jr., Rogers WH. Validation of a New Three-Item Self-
31 Report Measure for Medication Adherence. *AIDS Behav*. 2016;20(11):2700-8.
32 49. A Szende, B Janssen, J Cabases. In: Szende A, Janssen B, Cabases J, editors. *Self-Reported*
33 *Population Health: An International Perspective based on EQ-5D*. Dordrecht (NL): Springer
34
35
36
37
38 Copyright 2014, The Editor(s) (if applicable) and the Author(s). 2014.
39 50. Schulz KF, Grimes DA. Multiplicity in randomised trials I: endpoints and treatments. *Lancet*.
40 2005;365(9470):1591-5.
41 51. Cramer AOJ, van Ravenzwaaij D, Matzke D, Steingroever H, Wetzels R, Grasman RPPP, et al.
42 Hidden multiplicity in exploratory multiway ANOVA: Prevalence and remedies. *Psychonomic Bulletin*
43 *& Review*. 2016;23(2):640-7.
44 52. Althouse AD. Adjust for Multiple Comparisons? It's Not That Simple. *The Annals of Thoracic*
45 *Surgery*. 2016;101(5):1644-5.
46 53. Fox MP, Pascoe SJ, Huber AN, Murphy J, Phokojoe M, Gorgens M, et al. Assessing the impact
47 of the National Department of Health's National Adherence Guidelines for Chronic Diseases in South
48 Africa using routinely collected data: a cluster-randomised evaluation. *BMJ Open*.
49 2018;8(1):e019680.
50 54. Joska JA, Andersen LS, Smith-Alvarez R, Magidson J, Lee JS, O'Cleirigh C, et al. Nurse-
51 Delivered Cognitive Behavioral Therapy for Adherence and Depression Among People Living With
52 HIV (the Ziphamandla Study): Protocol for a Randomized Controlled Trial. *JMIR Res Protoc*.
53 2020;9(2):e14200.
54 55. Saidi F, Mutale W, Freeborn K, Rosenberg NE, Graybill LA, Maman S, et al. Combination
55 adherence strategy to support HIV antiretroviral therapy and pre-exposure prophylaxis adherence
56 during pregnancy and breastfeeding: protocol for a pair of pilot randomised trials. *BMJ Open*.
57 2021;11(6):e046032.
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
56. Parker RA, Weir CJ. Multiple secondary outcome analyses: precise interpretation is important. *Trials*. 2022;23(1):27.
57. White IR, Thompson SG. Adjusting for partially missing baseline measurements in randomized trials. *Stat Med*. 2005;24(7):993-1007.
58. Dong, Peng. *Principled missing data methods for researchers*: SpringerPlus 2013. 2-222 p.
59. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *BMJ : British Medical Journal*. 2013;346:f1049.
60. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? *Bmj*. 2000;320(7243):1197-200.
61. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. *Stat Med*. 2000;19(23):3219-36.
62. Remien RH, Patel V, Chibanda D, Abas MA. Integrating mental health into HIV prevention and care: a call to action. *Journal of the International AIDS Society*. 2021;24(S2):e25748.
63. UNAIDS. *End Inequalities. End AIDS. Global AIDS strategy 2021-2026*. Geneva: UNAIDS; 2020.



Figure 1: Participant Flow

Figure 2: Stepped Care-AD Flow



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	1
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	1
Funding	4	Sources and types of financial, material, and other support	1
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1-2
	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	2
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	14

1 **Introduction**

2

3 Background and 6a Description of research question and justification for undertaking the trial, including summary of relevant 4-5
4 rationale studies (published and unpublished) examining benefits and harms for each intervention
5

6 6b Explanation for choice of comparators 5
7

8 Objectives 7 Specific objectives or hypotheses 5
9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),
11 allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 5
12
13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 5
17 be collected. Reference to where list of study sites can be obtained
18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 6
20 individuals who will perform the interventions (eg, surgeons, psychotherapists)
21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 8-11, 19
23 administered
24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 8-10
26 change in response to harms, participant request, or improving/worsening disease)
27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 11-13
29 (eg, drug tablet return, laboratory tests)
30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 8-11
32

33 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood
34 pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, 11-12
35 median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen
36 efficacy and harm outcomes is strongly recommended
37

38 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 7-8, 20
39 participants. A schematic diagram is highly recommended (see Figure)
40
41
42

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	14
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	6, 12-13
5				

6
7 **Methods: Assignment of interventions (for controlled trials)**

8 Allocation:

10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	7
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	7
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	7
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	13-14
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	13-14
28				
29				
30				

31 **Methods: Data collection, management, and analysis**

33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	11-12
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	12-13
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12-13
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	15-16
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	16
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	16
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	14
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	13-14
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	12, 14
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	13
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	13
38				
39				
40				
41				
42				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	6
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	12
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	1
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	13-14
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	3, 6
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	N/A
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	17
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	N/A
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
35				
36				

37 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 39 “[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)” license.
 40
 41
 42